var title_f31_17_32016="HIV encephalopathy MRI";
var content_f31_17_32016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI scan of a patient with HIV-associated encephalopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral symmetrical high T2 signals without mass effect are present in the white matter of both frontal lobes, associated with subcortical atrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32016=[""].join("\n");
var outline_f31_17_32016=null;
var title_f31_17_32017="Mobilization of the hepatic flexure for colon cancer";
var content_f31_17_32017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the hepatic flexure for colon cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32017=[""].join("\n");
var outline_f31_17_32017=null;
var title_f31_17_32018="Selecting gait aid";
var content_f31_17_32018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 659px\">",
"   <div class=\"ttl\">",
"    Determining which gait aid to prescribe for issues of endurance, balance, or weight-bearing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 639px; height: 1006px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When more than one gait aid is listed in a box, they are listed in order of increasing support. Comorbid conditions would influence which gait aid to chose when more than one option is available and/or would influence use of a more supportive device (eg, some with a little impairment in endurance plus a little impairment in balance might require a wheelchair for community mobility but be able to use a walker at home).",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmondary disease; HF: heart failure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32018=[""].join("\n");
var outline_f31_17_32018=null;
var title_f31_17_32019="APC and wnt signaling pathway";
var content_f31_17_32019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    The APC gene, and possible pathogenetic mechanisms in familial adenomatous polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The APC (adenomatous polyposis coli) gene modulates &beta;-catenin, Tcf transcriptional activation, and Wnt signal transduction.",
"    <br>",
"     (A) In the presence of wildtype APC or in the absence of Wnt ligand, &beta;-catenin is localized to the adherens junction where it is associated with E-cadherin, &alpha;-catenin, p120cas, and indirectly with the cytoskeleton. GSK3&beta; phosphorylates &beta;-catenin in a complex that contains &beta;-catenin, APC, and axin family members, and &beta;-catenin is rapidly degraded by ubiquination at the proteosome.",
"     <br>",
"      (B) When APC is mutated, &beta;-catenin accumulates in the cytoplasm and the nucleus. Similarly, binding of Wnt ligand to its receptor, known as frizzled, inactivates the GSK3&beta; kinase through dishevelled, generating a cytosolic pool of &beta;-catenin. &beta;-catenin is associated with members of the Tcf family of transcription factors and modulates the transcription of target genes with Tcf recognition sequences. In some instances, &beta;-catenin increases transcription of target genes by competing for Tcf binding with corepressors, such as Groucho and CREB-binding protein (CBP), to relieve transcriptional repression.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor supressor. J Clin Oncol 2000; 18:1967. Copyright &copy; 2000 American Society of Clinical Oncology.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32019=[""].join("\n");
var outline_f31_17_32019=null;
var title_f31_17_32020="Continuous oral NPPV";
var content_f31_17_32020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous oral NPPV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Bach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32020=[""].join("\n");
var outline_f31_17_32020=null;
var title_f31_17_32021="Amitriptyline: Patient drug information";
var content_f31_17_32021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amitriptyline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     see \"Amitriptyline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/32/7687?source=see_link\">",
"     see \"Amitriptyline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-Amitriptyline;",
"     </li>",
"     <li>",
"      Dom-Amitriptyline;",
"     </li>",
"     <li>",
"      Elavil;",
"     </li>",
"     <li>",
"      Levate&reg;;",
"     </li>",
"     <li>",
"      Novo-Triptyn;",
"     </li>",
"     <li>",
"      PMS-Amitriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease long-term pain problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eating problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3437665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help diabetic nerve pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amitriptyline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to blue or green.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10829 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32021=[""].join("\n");
var outline_f31_17_32021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133739\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020296\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020298\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020297\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020302\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020303\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020305\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020300\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020301\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020306\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020307\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=related_link\">",
"      Amitriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/32/7687?source=related_link\">",
"      Amitriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_17_32022="Lyme disease symptoms and diagnosis";
var content_f31_17_32022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32022/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/17/32022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     LYME DISEASE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is the most common tick-borne illness in the United States and Europe. Lyme disease is caused by an infection with the bacteria, Borrelia burgdorferi, which is carried by deer ticks. The bacteria are transmitted when a tick bites a person.",
"   </p>",
"   <p>",
"    Lyme disease was first described after an outbreak of what was thought to be \"juvenile rheumatoid arthritis\" in Lyme, Connecticut and surrounding communities. Since juvenile rheumatoid arthritis does not occur in outbreaks, researchers studied these patients, which led to the identification of Lyme arthritis, an infection that often affects the joints. As the researchers developed a better understanding of the infection, other non-joint features were identified. It became clear that Lyme disease affects different organs during different stages of the infection.",
"   </p>",
"   <p>",
"    In most people, treatment with antibiotics is very effective in eliminating symptoms, preventing progression to later manifestations of the disease, and curing the infection. Some symptoms improve rapidly with this treatment, whereas other symptoms gradually improve over weeks to months.",
"   </p>",
"   <p>",
"    This topic review discusses how Lyme disease develops, the symptoms, and the diagnostic process. A separate topic review discusses the treatment and prevention of Lyme disease. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=see_link\">",
"     \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"     \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"    </a>",
"    .) A topic review that discusses tick bites is also available (see",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/10/13474?source=see_link\">",
"     \"Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    More detailed information about Lyme disease is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26263?source=see_link\">",
"     \"Evaluation of a tick bite for possible Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHERE DOES LYME DISEASE OCCUR?",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, Lyme disease commonly occurs in three regions: the northeast and mid-Atlantic states (from Maine to Virginia), the midwest (Minnesota, Wisconsin, and Michigan), and on the west coast (in northern California). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although Lyme disease has been found in many states, more than 90 percent of cases in the United States have been reported from ten states: Massachusetts, Connecticut, Rhode Island, New York, New Jersey, Pennsylvania, Delaware, Maryland, Minnesota, and Wisconsin.",
"   </p>",
"   <p>",
"    Within these states, there are \"hot spots\" where Lyme disease occurs most frequently; other locations in these states have a much lower rate of infection. These \"hot spots\" are the result of local environmental conditions.",
"   </p>",
"   <p>",
"    The availability of food and water resources to the deer population is probably an important factor in the number of cases of Lyme disease. In addition, property at or near the border of forests is a preferred area for field mice, which carry deer ticks. Living in an area that borders a forest increases the risk of becoming infected with Lyme disease, especially for people who spend a lot of time outdoors.",
"   </p>",
"   <p>",
"    Lyme disease also occurs in Europe and Asia (where it is often called Lyme borreliosis rather than Lyme disease). The signs and symptoms, organisms causing the disease, and ticks carrying the disease are somewhat different in Europe and Asia compared with the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHEN DOES LYME DISEASE OCCUR?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with the bacteria that causes Lyme disease, Borrelia burgdorferi, usually occurs in the late spring and summer, particularly in a several week period around the time of the summer solstice, but some cases also occur in the early fall. Most people who become infected have the early features of infection; these symptoms typically occur within days to several weeks after the tick bite. Occasionally, a person does not recall the early illness and may be diagnosed after developing later features of infection. The peak season for becoming infected occurs during the nymphal stage of tick development, when the biting ticks are very small (about the size of a poppy seed) and trying to find food (human or animal blood). Due to their size, ticks are difficult to see (",
"    <a class=\"graphic graphic_picture graphicRef51825 \" href=\"mobipreview.htm?15/16/15617\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lyme disease occurs less often in the late fall, and rarely in the winter and early spring because the small nymphal stage ticks are not seeking a blood meal at that time. In the fall, the adult stage ticks, which are about the size of a sesame seed, spread the infection. These larger ticks are more easily detected and can be removed before they bite. In addition, the adult stage ticks are less likely to transmit the Lyme disease bacteria than the nymphal ticks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LYME DISEASE TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ticks are carried by mice (during the nymphal stage) and deer (in the adult stage). Ticks wait for a new host on the underside of low-lying shrubs and grass, often along the boundary between grass and the forest. Ticks are particularly dense in the shrubs and grass bordering paths frequented by deer. Ticks are also common in the gaps of old stone walls because field mice often nest in these areas.",
"   </p>",
"   <p>",
"    Ticks do not survive for any length of time in sun-drenched lawns because they rapidly dry out. Ticks do not jump, hop, fly or descend from trees.",
"   </p>",
"   <p>",
"    Ticks sense warmth and carbon dioxide given off by animals and humans as they pass the tick. Once the tick senses this warmth and carbon dioxide, it latches onto anything that brushes up against it.",
"   </p>",
"   <p>",
"    Ticks take up to 24 hours from the time of first contact with the skin before they actually start to feed on the host's blood. The tick must remain firmly attached to the skin for 48 to 72 hours to pass the bacteria that causes Lyme disease to humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32022/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, there is a long period of time between the tick's first contact with its host and the transmission of infection.",
"   </p>",
"   <p>",
"    An individual who is bitten by a tick has a very low risk (about 1 in 100 chance) of acquiring Lyme disease if the tick is removed before it is engorged (filled with blood). Thus, a careful search for ticks after spending time outdoors is useful in avoiding a tick bite; a tick that has not bitten cannot cause Lyme disease. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"     \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LYME DISEASE RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In regions of the United States where Lyme disease is common, individuals who spend a lot of time outdoors are at the greatest risk for Lyme disease, including people who work outdoors, garden, or participate in outdoor activities such as hunting or hiking.",
"   </p>",
"   <p>",
"    There is a greater risk of acquiring Lyme disease in the area around old stone walls and between forest land and lawns, especially if the area contains low-lying shrubs or grasses.",
"   </p>",
"   <p>",
"    Ticks can attach to pets (including dogs and cats) and be carried into the home. The tick can then infect the pet with Lyme disease, or, if the tick does not attach to the pet, it can become attached to a human and potentially transmit the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LYME DISEASE SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of Lyme disease can vary widely and may include a rash at the site of the tick bite, flu-like symptoms, arthritis, heart symptoms, and neurologic symptoms. Infection causes few or no symptoms in a small percentage of people.",
"   </p>",
"   <p>",
"    Symptoms are caused by the body's immune response to the bacteria and the inflammation that results; inflammation may continue even after treatment. Symptoms vary with the phase of the disease. The three phases are early localized, early disseminated, and late Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early localized",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early localized Lyme disease causes a skin condition called erythema migrans (EM). EM typically occurs within one month of the tick bite, usually about 7 to 14 days after the tick bite, which may not have been noticed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Erythema migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema migrans (EM) is a distinctive skin rash that occurs at the site of the tick bite. The rash is usually salmon to red-colored; the color may cover the entire lesion or may have an area in the center that is flesh-colored. In some cases, the rash consists of multiple rings, which give it a \"bull's eye\" appearance (",
"    <a class=\"graphic graphic_picture graphicRef58798 \" href=\"mobipreview.htm?10/29/10704\">",
"     picture 2",
"    </a>",
"    ). The \"bull's eye\" is seen in about one-third of patients with EM. Approximately 80 percent of people develop EM, although only about 30 percent actually recall having had a tick bite.",
"   </p>",
"   <p>",
"    The most common site for a tick bite is in the armpit, groin, backs of the knees, or belt line. Children may be bitten on the neck or scalp, although these are unusual sites for bites in adults. EM occasionally itches or burns. EM typically expands outward over several days and can be as large as 20 cm (8 inches) in diameter. The EM rash occasionally itches or burns. Most people have a single lesion (at the site of the tick bite), although about 10 to 20 percent have multiple lesions. This pattern is caused by the spread of the bacteria in the bloodstream rather than by multiple bites.",
"   </p>",
"   <p>",
"    People with an allergy to tick saliva can develop a red rash at the site of the tick bite soon after being bitten; this rash typically lasts for 24 to 48 hours, but may continue for up to a week. This reaction may be confused with the EM rash. However, an allergic-type rash does not expand and typically becomes less red over time. In contrast, EM expands and often becomes more intensely red over time. When in doubt, a healthcare provider should be consulted. The provider can help distinguish between redness that does not require treatment and EM, which requires treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nonspecific symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early Lyme disease can cause nonspecific, virus-like signs and symptoms, including fatigue, a feeling of being unwell, fever, headache, muscle pain, joint pain, and swollen lymph nodes. However, these symptoms alone (without the presence of EM) are not sufficient to diagnose Lyme disease. Severe symptoms are unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Early disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;During early disseminated Lyme disease, the bacteria spread through the bloodstream to other areas of the body, triggering inflammation in specific tissues. Early disseminated disease occurs days to weeks after the tick bite. Treatment at this stage helps to prevent later problems.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac symptoms &mdash; Inflammation of the heart occurs in 8 percent or less of adults with untreated Lyme disease. This inflammation may interfere with the normal conduction of electrical impulses through the heart, causing a condition called atrioventricular block or heart block. Heart block can cause a slower than normal heart rate, lightheadedness and fainting, or may cause no symptoms at all.",
"      <br/>",
"      <br/>",
"      Lyme disease may also cause inflammation of the heart muscle and the tissue covering the heart (myopericarditis), but these are rare symptoms and are usually mild when they do occur.",
"     </li>",
"     <li>",
"      Neurologic symptoms &mdash; Neurologic symptoms can result from inflammation of several areas of the nervous system, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The meninges (the tissue covering the brain and spinal cord is called the meninges); inflammation of the meninges is called meningitis, which causes headache and a stiff neck.",
"     </li>",
"     <li>",
"      The nerve roots and nerves (especially the nerves that control facial movement), causing weakness, pain, or strange sensations, such as numbness.",
"      <br/>",
"      <br/>",
"      These neurologic symptoms occur in about 10 percent of adult individuals with untreated Lyme disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Late disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;During late Lyme disease, inflammation most commonly affects the joints but may involve the nervous system and, in Europe, the skin. Symptoms of late Lyme disease occur months to years after a tick bite. In some individuals, these symptoms may be the first symptoms of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle and joint symptoms &mdash; Muscle and joint symptoms are the most common symptoms of late Lyme disease; these symptoms occur in 80 percent of individuals with Lyme disease who have not been treated with antibiotics. Joint pain occurs in 20 percent of individuals, intermittent episodes of arthritis (joint inflammation) in 50 percent, and persistent arthritis of a single joint (usually a knee) or a few joints in 10 percent of those who have not been treated.",
"     </li>",
"     <li>",
"      Neurologic symptoms &mdash; Late Lyme disease can cause a variety of neurologic symptoms including pain, difficulty with memory or thinking, and odd sensations, such as numbness. However, late neurologic manifestations of Lyme disease are quite rare, and therefore, these types of non-specific symptoms usually have causes other than Lyme disease.",
"     </li>",
"     <li>",
"      Skin symptoms &mdash; In Europe, the late symptoms of Lyme disease may include skin nodules. They may also include swelling and subsequent thinning of patches of skin, which usually occurs on the hands, feet, knees, or elbows.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Post-Lyme disease syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific symptoms such as headache, fatigue, and joint pain may linger for months after the treatment of Lyme disease has ended. However, these symptoms gradually resolve and do not require further antibiotic therapy.",
"   </p>",
"   <p>",
"    The term \"chronic\" Lyme disease is not technically correct as there is no evidence that the bacteria can survive after appropriate antibiotic treatment. There is no evidence that antibiotics improve post-Lyme disease symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia develops in some people after treatment for Lyme disease. However, this is a post-infectious syndrome that is not caused by active infection with B. burgdorferi. Even in areas with high rates of Lyme disease, only a small number of all cases of fibromyalgia are actually triggered by prior infection with Lyme disease. Fibromyalgia is characterized by a specific pattern of muscle and joint pain. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"     \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LYME DISEASE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Lyme disease is based on an individual's history of possible exposure to ticks, the presence of characteristic signs and symptoms, and the results of blood tests. However, the results of blood tests for Lyme disease can vary from laboratory to laboratory. Results can be difficult to interpret if there is no history of tick exposure or EM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood tests for Lyme disease are not recommended in people with nonspecific symptoms since tests may be falsely positive. Blood testing is also not recommended for a person who has classic features of early localized Lyme disease, including erythema migrans. Testing may be falsely negative during the first several weeks of infection, potentially delaying the correct diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major categories of blood tests, enzyme-linked immunosorbent assay (ELISA) and Western blot, which are used to check for current or prior infection with B. burgdorferi, the bacterium that causes Lyme disease. Both tests detect specific antibodies (proteins made by the immune system to fight the bacteria) made when the body's immune system responds to the organism that causes Lyme disease. Although the antibody responses decline slowly after adequate antibiotic treatment, the responses will remain positive even after antibiotic treatment. Thus, positive test results do",
"    <strong>",
"     not",
"    </strong>",
"    prove that the person has active infection.",
"   </p>",
"   <p>",
"    Since it takes time for the immune system to respond to the infection and create antibodies, all antibody tests are less reliable in the early period after infection. As the infection progresses, virtually everyone with Lyme disease has a positive test result.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ELISA &mdash; The ELISA is usually the first test done for Lyme disease. The ELISA test is very good (&ldquo;sensitive&rdquo;) at detecting antibodies to Lyme disease, but it can also detect antibodies against other proteins (low &ldquo;specificity&rdquo; for Lyme disease). When the ELISA detects antibodies in someone who does not have Lyme disease, it is called a &ldquo;false positive&rdquo; result. (Because of the chance of the ELISA giving a false positive result, a Western blot, which has improved specificity, is typically ordered to confirm a positive ELISA test.)",
"     </li>",
"     <li>",
"      Western blot &mdash; The second test, a Western blot, is done when the ELISA results are positive or equivocal (not clearly positive or negative); it is helpful in determining when the results of an ELISA test are falsely positive. The Western blot is more specific for B. burgdorferi than the ELISA because it identifies antigens individually; antigens are the parts of the Lyme disease bacteria that antibodies detect. The Western blot is typically reported as the number of antigens recognized (positive bands) out of the total tested. The greater the number of positive bands, the greater the chance that the patient has encountered the Lyme disease bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a diagnosis of Lyme disease is uncertain and an individual has neurologic symptoms, testing the cerebrospinal fluid (the fluid surrounding the brain and spinal cord) using the ELISA and western blot can help to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Cerebrospinal fluid is collected by inserting a needle into the lower back, below where the spinal cord ends. This procedure is called a lumbar puncture or LP. The patient usually lies on an examining table, and is awake during the procedure. Local anesthetic (numbing medicine) is injected under the skin before the LP so that the patient feels only a pressure sensation. A small amount of fluid is collected and sent to a laboratory for testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LYME DISEASE TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prevention of Lyme disease are discussed in a separate topic. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=see_link\">",
"     \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"     \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498783039\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3704597\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=see_link\">",
"     Patient information: Lyme disease (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/51/15155?source=see_link\">",
"     Patient information: Insect bites and stings (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/2/22562?source=see_link\">",
"     Patient information: Rocky Mountain spotted fever (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3704623\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=see_link\">",
"     Patient information: Lyme disease treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"     Patient information: Lyme disease prevention (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/10/13474?source=see_link\">",
"     Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"     Patient information: Fibromyalgia (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     Clinical manifestations of Lyme disease in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     Diagnosis of Lyme disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26263?source=see_link\">",
"     Evaluation of a tick bite for possible Lyme disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40759?source=see_link\">",
"     Lyme carditis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     Epidemiology of Lyme disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link\">",
"     Musculoskeletal manifestations of Lyme disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3960?source=see_link\">",
"     Prevention of Lyme disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link\">",
"     Treatment of Lyme disease",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/lymedisease.html\">",
"     www.nlm.nih.gov/medlineplus/lymedisease.html",
"    </a>",
"    , available in Spanish)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Allergy and Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/lymeDisease/\">",
"     www3.niaid.nih.gov/topics/lymeDisease/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Center for Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Division of Vector-Borne Infectious Diseases",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvbid/lyme/\">",
"     www.cdc.gov/ncidod/dvbid/lyme/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Lyme Disease Foundation, Inc.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aldf.com/faq.shtml\">",
"     www.aldf.com/faq.shtml",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32022/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/1\">",
"      Sood SK, Salzman MB, Johnson BJ, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis 1997; 175:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/2\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2007; 56:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/4\">",
"      Steere AC. Lyme disease. N Engl J Med 2001; 345:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/5\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/6\">",
"      Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med 2001; 110:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32022/abstract/7\">",
"      Krause PJ, Bockenstedt LK. Cardiology patient pages. Lyme disease and the heart. Circulation 2013; 127:e451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4011 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32022=[""].join("\n");
var outline_f31_17_32022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      LYME DISEASE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHERE DOES LYME DISEASE OCCUR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHEN DOES LYME DISEASE OCCUR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LYME DISEASE TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LYME DISEASE RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LYME DISEASE SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early localized",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nonspecific symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Early disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Late disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Post-Lyme disease syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LYME DISEASE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cerebrospinal fluid tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LYME DISEASE TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498783039\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3704597\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3704623\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/4011\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/4011|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/16/15617\" title=\"picture 1\">",
"      Tick comparison PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/29/10704\" title=\"picture 2\">",
"      Erythema migrans PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=related_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/2/22562?source=related_link\">",
"      Patient information: Rocky Mountain spotted fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/10/13474?source=related_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3960?source=related_link\">",
"      Prevention of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_17_32023="Guanfacine: Drug information";
var content_f31_17_32023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guanfacine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/32/1541?source=see_link\">",
"    see \"Guanfacine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=see_link\">",
"    see \"Guanfacine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intuniv&reg;;",
"     </li>",
"     <li>",
"      Tenex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Immediate release: 1 mg usually at bedtime, may increase if needed at 3- to 4-week intervals; usual dose range (JNC 7): 0.5-2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9612512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=see_link\">",
"      see \"Guanfacine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ADHD, monotherapy or adjunct to stimulants:",
"     </b>",
"     Children &ge;6 years and Adolescents: Oral: Extended release (Intuniv&reg;): Initial: 1 mg once daily; may adjust by increments no larger than 1 mg/week as tolerated, based on clinical response; maximum dose: 4 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinical response is associated with doses of 0.05-0.08 mg/kg/day. Doses up to 0.12 mg/kg/day may provide additional benefit; however, doses &gt;4 mg/day have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers: Extended release:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Strong CYP3A4 inhibitors:",
"     </i>",
"     If initiating guanfacine while taking a strong CYP3A4 inhibitor, do not exceed a maximum guanfacine dose of 2 mg/day. If continuing guanfacine and adding a strong CYP3A4 inhibitor, decrease guanfacine dose by 50%. If the strong CYP3A4 inhibitor is discontinued, double the guanfacine dose (maximum dose: 4 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Strong CYP3A4 inducers:",
"     </i>",
"     If initiating guanfacine while taking a strong CYP3A4 inducer, may titrate guanfacine up to 8 mg/day; consider faster titration (eg, 2 mg/week). If continuing guanfacine and adding a strong CYP3A4 inducer, consider increasing guanfacine gradually over 1-2 weeks to double the original dose. If the strong CYP3A4 inducer is discontinued, decrease guanfacine dose by 50% over 1-2 weeks (maximum dose: 4 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Conversion from immediate release to extended release:",
"     </b>",
"     Discontinue the immediate release formulation, and titrate according to extended release recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Missed doses of extended release:",
"     </b>",
"     If &ge;2 consecutive doses are missed, consider repeating dosage titration based on patient tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Discontinuation of extended release:",
"     </b>",
"     Gradually discontinue by tapering dose in decrements of &le;1 mg every 3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Children &ge;12 years: Oral: Immediate release: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Immediate release: Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9612513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release (Intuniv&reg;): Children &ge;6 years and Adolescents: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Children &ge;12 years and Adults: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, the lower end of the dosing range is recommended in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Immediate release or extended release: Dialysis clearance is low (~15% of total clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9612514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release (Intuniv&reg;): Children &ge;6 years and Adolescents: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Children &ge;12 years and Adults: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, use with caution in chronic hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenex&reg;: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intuniv&reg;: 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9612516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release tablets should be taken at the same time each day (either morning or evening), and should not be crushed, broken, or chewed. Formulations (immediate release versus extended release) are not interchangeable.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, immediate release: Management of hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release: Treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy or adjunctive therapy to stimulants",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1044873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tic disorder; Tourette's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GuanFACINE may be confused with guaiFENesin, guanabenz, guanidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tenex&reg; may be confused with Entex&reg;, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tenex [U.S., Canada] may be confused with Kinex brand name for biperiden [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (5% to 45%; dose-related), dizziness (2% to 15%; dose-related), headache (3% to 26%), fatigue (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4% to 54%; dose-related), constipation (&le;16%; dose-related), abdominal pain (&le;11%; dose-related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (&le;10%; dose-related), hypertension (2% to 5%), syncope (1% to 5%), AV block (&lt;2%), bradycardia (&lt;2%), chest pain (&lt;2%), orthostasis (&lt;2%), pallor (&lt;2%), sinus arrhythmias (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (2% to 12%), fever (8%; Biederman, 2008), irritability (6%), lethargy (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (9%), nausea (&le;7%), weight gain (&le;7%), appetite decreased (2% to 5%), diarrhea (2% to 5%), stomach discomfort (2% to 5%), dyspepsia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (&le;7%), enuresis (&lt;2%), urinary frequency (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, amnesia, depression, dermatitis, dysphagia, edema, exfoliative dermatitis, hypersensitivity reaction, hypokinesia, iritis, nocturia, palpitation, paresis, rebound hypertension, seizure, tachycardia, urinary incontinence, vision disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guanfacine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: May cause bradycardia, hypotension, orthostasis, and syncope; these effects are dose-dependent and more pronounced during the first month of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause sedation and drowsiness which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatological effects: Skin rash with exfoliation has been reported; discontinue guanfacine and monitor patients who develop a rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, recent MI, or a history of bradycardia, cardiovascular disease, heart block, hypotension, or syncope. Cautious use is also recommended in patients with conditions that predispose them to syncope (eg, orthostasis, dehydration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with chronic hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with chronic renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Concurrent use with other antihypertensive medications and/or drugs that decrease heart rate may increase the risk of cardiovascular effects (eg, bradycardia, hypotension, syncope).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Avoid concomitant use with other CNS depressants and ethanol; effects may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to high risk of CNS adverse effects; may also cause orthostatic hypotension and bradycardia; not recommended for routine use as an antihypertensive (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Formulations of guanfacine (immediate release versus extended release) are not interchangeable on a mg:mg basis as bioavailability varies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Abrupt discontinuation can result in nervousness, anxiety and rarely, rebound hypertension (occurs 2-4 days after withdrawal). To minimize these effects, taper the dose in decrements of &le;1 mg every 3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders; safety and efficacy of long-term use for the treatment of ADHD (&gt;2 years) have not been established (Sallee, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: GuanFACINE may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding St Johns Wort.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking St Johns Wort.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: GuanFACINE may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9612493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9612487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies indicate decreased fetal survival when administered at higher doses than recommended in humans. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9612489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if guanfacine is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9612515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release tablets: Do not administer with a high-fat meal due to increased exposure.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F178159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Intuniv Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $807.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $807.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $807.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $807.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GuanFACINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $87.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $117.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tenex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $288.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $428.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6012534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure (prior to initiation, following dosage adjustments, and periodically thereafter), and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F178160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Akfen (IE);",
"     </li>",
"     <li>",
"      Dipresan (HR);",
"     </li>",
"     <li>",
"      Estulic (BE, BF, BJ, CH, CI, CZ, DE, ET, FR, GH, GM, GN, HN, HU, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PH, PL, RU, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Hipertensal (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Guanfacine is a selective alpha",
"     <sub>",
"      2A",
"     </sub>",
"     -adrenoreceptor agonist which reduces sympathetic nerve impulses, resulting in reduced sympathetic outflow and a subsequent decrease in vasomotor tone and heart rate.  In addition, guanfacine preferentially binds postsynaptic alpha",
"     <sub>",
"      2A",
"     </sub>",
"     -adrenoreceptors in the prefrontal cortex and has been theorized to improve delay-related firing of prefrontal cortex neurons. As a result, underlying working memory and behavioral inhibition are affected; thereby improving symptoms associated with ADHD.  Guanfacine is not a CNS stimulant.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Antihypertensive effect: 24 hours following single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (relative to immediate-release): 58%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: ~17 hours (range: 10-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 2.6 hours (range: 1-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bassarath L, \"Medication Strategies in Childhood Aggression: A Review,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      ,  2003, 48(6):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/12894610/pubmed\" id=\"12894610\" target=\"_blank\">",
"        12894610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Melmed RD, Patel A, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(1):e73-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/18166547/pubmed\" id=\"18166547\" target=\"_blank\">",
"        18166547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Melmed RD, Patel A, et al, \"Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents With ADHD,\"",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2008, 13(12):1047-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/19179940/pubmed\" id=\"19179940\" target=\"_blank\">",
"        19179940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chappell PB, Riddle MA, Scahill L, et al, Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(9):1140-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummings DD, Singer HS, Krieger M, et al, \" Neuropsychiatric Effects of Guanfacine in Children With  Mild Tourette Syndrome: A Pilot Study,\"",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 2002,  25(6):325-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/12469007/pubmed\" id=\"12469007\" target=\"_blank\">",
"        12469007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, Lyne A, Wigal T, et al, &ldquo;Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(3):215-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/19519256/pubmed\" id=\"19519256\" target=\"_blank\">",
"        19519256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, McGough J, Wigal T, et al, &ldquo;Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2009, 48(2):155-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/19106767/pubmed\" id=\"19106767\" target=\"_blank\">",
"        19106767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, Chappell PB, Kim YS, et al, \"A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2001, 158(7):1067-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/11431228/pubmed\" id=\"11431228\" target=\"_blank\">",
"        11431228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/17/32023/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8510 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-53F9A3D73A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32023=[""].join("\n");
var outline_f31_17_32023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178189\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612512\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612513\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612514\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178139\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612516\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178153\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044873\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178195\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178187\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178156\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178143\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837647\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612493\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612487\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612489\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265811\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612515\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178159\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6012534\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178160\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178142\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178155\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/32/1541?source=related_link\">",
"      Guanfacine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=related_link\">",
"      Guanfacine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_17_32024="Pyoderma gangrenosum - close view of ulcer";
var content_f31_17_32024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52291%7EDERM%2F72260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52291%7EDERM%2F72260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This purulent ulcer with a ragged and violaceous border is consistent with pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This purulent ulcer with a ragged and violaceous border is consistent with pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32024=[""].join("\n");
var outline_f31_17_32024=null;
var title_f31_17_32025="Approach to the adult with acute diarrhea in developed countries";
var content_f31_17_32025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with acute diarrhea in developed countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Christine A Wanke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32025/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/17/32025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrheal diseases represent one of the five leading causes of death worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Morbidity and mortality are significant even in the United States, where diarrhea is more often than not a \"nuisance disease\" in the normally healthy individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following definitions have been suggested according to the duration of diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute &mdash; &le;14 days in duration",
"     </li>",
"     <li>",
"      Persistent diarrhea &mdash; more than 14 days in duration",
"     </li>",
"     <li>",
"      Chronic &mdash; more than 30 days in duration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases of acute diarrhea are due to infections with viruses and bacteria and are self-limited. Noninfectious etiologies become more common as the course of the diarrhea persists and becomes chronic. The evaluation of patients for a noninfectious etiology should be considered in those patients in whom evaluation fails to identify a pathogen (eg, bacterial, viral, or protozoal) and the diarrhea worsens or becomes chronic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the dilemmas in assessing patients with acute diarrhea is deciding when to test and to initiate therapy. The approach to such patients will be reviewed here and generally focuses on distinguishing acute infectious etiologies, for which treatment is beneficial, from other causes (",
"    <a class=\"graphic graphic_algorithm graphicRef68348 \" href=\"mobipreview.htm?18/23/18800\">",
"     algorithm 1",
"    </a>",
"    ). The evaluation of persistent and chronic diarrhea, most commonly noninfectious etiologies, and specific causes of acute diarrhea and chronic diarrhea are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of acute infectious diarrhea include viruses (norovirus, rotavirus, adenoviruses, astrovirus, and others), bacteria (salmonella, campylobacter, shigella, enterotoxigenic E. coli, C. difficile, and others), and protozoa (cryptosporidium, giardia, cyclospora, entamoeba, and others)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp;Exact data on the frequency of different causes of acute diarrhea vary according to the definition used and the population studied. In addition, the prevalence of an identifiable infectious agent is probably grossly underestimated since many patients do not seek medical attention and testing is often not performed when patients do contact their clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\", section on 'Frequency of isolating an organism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of acute infectious gastroenteritis are probably viral, as indicated by the observation that stool cultures in patients with acute diarrhea have, in most studies, been positive in 1.5 to 5.6 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef82535 \" href=\"mobipreview.htm?31/25/32156\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5\">",
"     5",
"    </a>",
"    ]. Support for viral infection causing most cases comes from a pilot study of foodborne outbreaks in which stool collection kits were delivered to and from the patients' homes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/8\">",
"     8",
"    </a>",
"    ]. A pathogen was identified in 71 percent of patients, three-quarters of which were norovirus.",
"   </p>",
"   <p>",
"    In contrast, bacterial causes are responsible for most cases of severe diarrhea. This was illustrated in a study of 173 healthy adults with severe (defined as &ge;4 fluid stools per day for more than three days) acute community-acquired diarrhea; a bacterial pathogen was identified in 87 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protozoa are less commonly identified as the etiologic agents of acute gastrointestinal illness. Indications for testing for protozoa are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to obtain stool for ova and parasites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with acute diarrhea should include a careful history to determine the duration of symptoms and the frequency and characteristics of the stool. There should be an attempt to elicit evidence of extracellular volume depletion (eg, decreased skin turgor, orthostatic hypotension). Fever and peritoneal signs may be clues to infection with an invasive enteric pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications for diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnostic evaluation is indicated in patients with relatively severe illness, as suggested by one or more of the following (",
"    <a class=\"graphic graphic_algorithm graphicRef68348 \" href=\"mobipreview.htm?18/23/18800\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Profuse watery diarrhea with signs of hypovolemia",
"     </li>",
"     <li>",
"      Passage of many small volume stools containing blood and mucus",
"     </li>",
"     <li>",
"      Bloody diarrhea",
"     </li>",
"     <li>",
"      Temperature &ge;38.5&ordm;C (101.3&ordm;F)",
"     </li>",
"     <li>",
"      Passage of &ge;6 unformed stools per 24 hours or a duration of illness &gt;48 hours",
"     </li>",
"     <li>",
"      Severe abdominal pain",
"     </li>",
"     <li>",
"      Hospitalized patients or recent use of antibiotics",
"     </li>",
"     <li>",
"      Diarrhea in the elderly (&ge;70 years of age) or the immunocompromised",
"     </li>",
"     <li>",
"      Systemic illness with diarrhea, especially in pregnant women (in which case listeriosis should be suspected)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's history can be useful in identifying the pathogens associated with an episode of acute diarrhea and may help to guide empiric therapy when it is indicated. In addition to identifying the diarrhea as originating in the small or large bowel (",
"    <a class=\"graphic graphic_table graphicRef81945 \" href=\"mobipreview.htm?41/7/42107\">",
"     table 2",
"    </a>",
"    ), further diagnostic clues may be provided by questioning about factors that might expose a patient to potential pathogens, such as residence, occupational exposure, recent and remote travel, pets, and hobbies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnostically important finding is fever, which suggests infection with invasive bacteria (eg, Salmonella, Shigella, or Campylobacter), enteric viruses, or a cytotoxic organism such as Clostridium difficile or Entamoeba histolytica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5065?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6313?source=see_link\">",
"     \"Epidemiology of viral gastroenteritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A food history may also provide clues to a diagnosis. Consumption of unpasteurized dairy products, raw or undercooked meat or fish, or organic vitamin preparations may suggest certain pathogens (",
"    <a class=\"graphic graphic_table graphicRef75543 graphicRef55625 \" href=\"mobipreview.htm?26/29/27101\">",
"     table 3A-B",
"    </a>",
"    ). In addition, the timing of symptoms with regard to exposure to suspected offending food can be important clues to the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef56595 \" href=\"mobipreview.htm?31/24/32140\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"     10",
"    </a>",
"    ]. Women who are pregnant have a 20-fold increased risk of developing listeriosis from meat products or unpasteurized dairy products (such as soft cheeses). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms that begin within six hours suggest ingestion of a preformed toxin of Staphylococcus aureus or Bacillus cereus",
"     </li>",
"     <li>",
"      Symptoms that begin at 8 to 16 hours suggest infection with Clostridium perfringens",
"     </li>",
"     <li>",
"      Symptoms that begin at more than 16 hours can result from viral or bacterial infection (eg, contamination of food with enterotoxigenic or enterohemorrhagic E. coli).",
"     </li>",
"     <li>",
"      Syndromes that may begin with diarrhea but progress to fever and more systemic complaints such as head ache, muscle aches, stiff neck may suggest infection with Listeria monocytogenes, particularly in pregnant woman.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to ask about recent antibiotic use (as a clue to the presence of C. difficile infection, although it is possible for community-associated C. difficile infection to occur in patients without antibiotic exposure), other medications, and to obtain a complete past medical history (eg, to identify an immunocompromised host or the possibility of nosocomial infection). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bloody diarrhea is an uncommon disorder, being present in 3 percent of more than 30,000 stool cultures in a review from the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/12\">",
"     12",
"    </a>",
"    ]. A pathogen was identified in 20 percent. E. coli O157:H7 was present in 7.8 percent of visibly bloody specimens (compared to 0.1 percent of specimens that were not visibly bloody) and accounted for 39 percent of cultured pathogens in visibly bloody specimens compared to only 7 percent of cultured pathogens in all stools (bloody and nonbloody). Less common bacterial causes of visibly bloody diarrhea were Shigella, Campylobacter, and Salmonella species. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\", section on 'Bloody diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fecal leukocytes and occult blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the accuracy of fecal leukocytes alone or in combination with occult blood testing. The ability of these tests to predict the presence of an inflammatory diarrhea has varied greatly, with reports of sensitivity and specificity ranging from 20 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of diagnostic test accuracy estimated that, at a peak sensitivity of 70 percent, the specificity of fecal leukocytes was only 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2004 review estimated that, in developed countries, the sensitivity and specificity of fecal leukocytes for inflammatory diarrhea were 73 and 84 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other studies, fecal leukocytes were not accurate predictors of the response to antibiotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/9,17\">",
"       9,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variable estimates across studies may be partially due to differences in specimen processing and in operator experience. Because of these concerns about test performance, the role of testing for fecal leukocytes has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the presence of occult blood and fecal leukocytes supports the diagnosis of a bacterial cause of diarrhea in the context of the medical history and other diagnostic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/19\">",
"     19",
"    </a>",
"    ]; we perform this examination in addition to obtaining a bacterial culture in high risk patients. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'When to obtain stool cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fecal leukocyte determination is probably not of value in patients who develop diarrhea while hospitalized, in whom testing for Clostridium difficile is much more likely to be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fecal lactoferrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of fecal leukocyte testing described above, provided the rationale for the development of a fecal lactoferrin latex agglutination assay (LFLA). Lactoferrin is a marker for fecal leukocytes, but its measurement is more precise and less vulnerable to variation in specimen processing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial reports described sensitivity and specificity ranging from 90 to 100 percent in distinguishing inflammatory diarrhea (eg, bacterial colitis or inflammatory bowel disease) from noninflammatory causes (eg, viral colitis, irritable bowel syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. However, the test is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     When to obtain stool cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus has not been achieved on the optimal strategies for obtaining stool cultures. The preceding discussion underscores the difficulty in predicting the presence of bacterial causes of acute diarrhea, which is illustrated by the low rate of positive stool cultures in most reports (1.5 to 5.6 percent) (",
"    <a class=\"graphic graphic_table graphicRef82535 \" href=\"mobipreview.htm?31/25/32156\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5\">",
"     5",
"    </a>",
"    ], with the exception of patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.) Furthermore, the necessity of documenting a pathogen is not always clear since most infectious causes of acute diarrhea are self-limited.",
"   </p>",
"   <p>",
"    For these reasons, it is reasonable to continue symptomatic therapy for several days before considering further evaluation in patients who do not have severe illness, particularly if occult blood and fecal leukocytes are absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/24\">",
"     24",
"    </a>",
"    ]. Routine cultures are of little value in patients who develop diarrhea after being hospitalized for 72 hours or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, we recommend obtaining stool cultures on initial presentation in the following groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompromised patients, including those infected with the human immunodeficiency virus (HIV) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with diarrhea\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with comorbidities that increase the risk for complications",
"     </li>",
"     <li>",
"      Patients with more severe, inflammatory diarrhea (including bloody diarrhea)",
"     </li>",
"     <li>",
"      Patients with underlying inflammatory bowel disease in whom the distinction between a flare and superimposed infection is critical",
"     </li>",
"     <li>",
"      Some employees, such as food handlers, occasionally require negative stool cultures to return to work",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The culture results on intraluminal fluid obtained at endoscopy appear to add little to the findings on stool culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Processing stool cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician may need to specify the pathogens of concern when submitting the stool to facilitate the appropriate processing of the stool in the microbiology laboratory; specific media, methods, or stains may be required to isolate or identify organisms of interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/19,27,28\">",
"     19,27,28",
"    </a>",
"    ]. The specimen should be inoculated onto culture plates as quickly as possible.",
"   </p>",
"   <p>",
"    A routine stool culture will identify Salmonella, Campylobacter, and Shigella, the three most common causes of bacterial diarrhea in the United States. When Aeromonas and most strains of Yersinia are possible pathogens (eg, travelers diarrhea or foodborne outbreaks, especially in infants), the laboratory needs to be notified; these organisms grow in routine culture but are frequently overlooked unless their isolation is specified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23943?source=see_link\">",
"     \"Aeromonas infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22373?source=see_link&amp;anchor=H3697194#H3697194\">",
"     \"Microbiology and pathogenesis of Yersinia infections\", section on 'Laboratory isolation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A stool culture that is positive for one of these pathogens in a patient with acute diarrheal symptoms can be interpreted as a true positive. Gastroenteritis due to Listeria should be considered in outbreaks of febrile gastroenteritis with non-bloody diarrhea if routine cultures are negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1736?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'Febrile gastroenteritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike ova and parasites, which are often shed intermittently, these pathogens generally are excreted continuously. Thus, a negative culture is usually not a false negative, and repeat specimens are rarely required. Other organisms that should be considered in selected situations include Enterohemorrhagic Escherichia coli (EHEC), viruses, and vibrios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When to obtain stool for ova and parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sending stool samples for ova and parasites is",
"    <strong>",
"     not",
"    </strong>",
"    cost effective for the majority of patients with acute diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/29\">",
"     29",
"    </a>",
"    ]. There are, however, several possible indications for ova and parasite study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent diarrhea (associated with Giardia, Cryptosporidium, and Entamoeba histolytica)",
"     </li>",
"     <li>",
"      Persistent diarrhea following travel to Russia, Nepal, or mountainous regions (associated with Giardia, Cryptosporidium, and Cyclospora)",
"     </li>",
"     <li>",
"      Persistent diarrhea with exposure to infants in daycare centers (associated with Giardia and Cryptosporidium)",
"     </li>",
"     <li>",
"      Diarrhea in a man who has sex with men (MSM) or a patient with AIDS (associated with Giardia and Entamoeba histolytica in the former, and a variety of parasites in the latter). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A community waterborne outbreak (associated with Giardia and Cryptosporidium)",
"     </li>",
"     <li>",
"      Bloody diarrhea with few or no fecal leukocytes (associated with intestinal amebiasis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three specimens should be sent on consecutive days (or each specimen separated by at least 24 hours) for ova and parasite examination since parasite excretion may be intermittent in contrast to bacterial pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is uncommonly needed in the diagnosis of acute diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/30\">",
"     30",
"    </a>",
"    ]. It may be helpful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distinguishing inflammatory bowel disease from infectious diarrhea (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=see_link\">",
"       \"Endoscopic diagnosis of inflammatory bowel disease\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diagnosing C. difficile infection and looking for pseudomembranes in patients who are toxic while results of tissue culture assays are pending. The widespread adoption of enzyme linked immunosorbent assays (ELISA) for C. difficile toxins A and B has reduced the time for C. difficile results to become available and thus decreased the need for endoscopy in these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"       \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In immunocompromised patients who are at risk for opportunistic infections with agents such as cytomegalovirus.",
"     </li>",
"     <li>",
"      In patients in whom ischemic colitis is suspected but the diagnosis remains unclear after clinical and radiologic assessment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=see_link\">",
"       \"Colonic ischemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with acute diarrhea begins with general measures such as hydration and alteration of diet. Antibiotic therapy is not required in most cases since the illness is usually self-limited. Nevertheless, empiric and specific antibiotic therapy can be considered in certain situations. The treatment of specific infections is discussed in detail on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral rehydration solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most critical therapy in diarrheal illness is hydration, preferably by the oral route with solutions that contain water, salt, and sugar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. Oral rehydration therapy is grossly underutilized in the United States where health care providers tend to overuse intravenous hydration. It is estimated that proper use of oral rehydration could reduce hospitalizations of children by 100,000 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral rehydration solutions were developed following the realization that, in many small bowel diarrheal illnesses, intestinal glucose absorption via sodium-glucose cotransport remains intact. Thus, in diarrheal disease caused by any organism that depends on small bowel secretory processes, the intestine remains able to absorb water if glucose and salt are also present to assist in the transport of water from the intestinal lumen.",
"   </p>",
"   <p>",
"    The composition of the oral rehydration solution (per liter of water) recommended by the World Health Organization consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      3.5 g sodium chloride",
"     </li>",
"     <li>",
"      2.9 g trisodium citrate or 2.5 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"     </li>",
"     <li>",
"      1.5 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"     </li>",
"     <li>",
"      20 g glucose or 40 g sucrose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    WHO-ORS is available from the manufacturer (Jianas Brothers, St. Louis, Mo). Rehydralyte (Ross Laboratories, Columbus, Ohio) is available over the counter, but contains 20 percent less sodium, so larger volumes are needed for rehydration. A similar solution can be made by adding one-half teaspoon of salt, one-half teaspoon of baking soda, and four tablespoons of sugar to one liter of water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/35\">",
"     35",
"    </a>",
"    ]. Cera-lyte is also available over the counter and is a rice based oral rehydration solution.",
"   </p>",
"   <p>",
"    The electrolyte concentrations of fluids used for sweat replacement (eg, Gatorade) are not equivalent to oral rehydration solutions, although they may be sufficient for the otherwise healthy patient with diarrhea who is not dehydrated. Diluted fruit juices and flavored soft drinks along with saltine crackers and broths or soups may also meet the fluid and salt needs in these less severely ill individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If available, racecadotril, an enkephalinase inhibitor, may be an effective adjunct to oral rehydration solutions in children. In one study, it reduced the output and duration of watery diarrhea in a study of 135 Peruvian boys, ages three to 35 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of rapid diagnostic testing methods for enteric pathogens requires that decisions about therapy are often made empirically at the time of presentation. In general, empiric therapy for community-acquired acute diarrhea may be beneficial but does not appear to dramatically alter the course of illness in unselected populations. A large Swedish trial, for example, randomly assigned 598 adults with acute diarrhea of less than five days' duration to therapy with a five-day course of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400 mg PO twice daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/38\">",
"     38",
"    </a>",
"    ]. Enteric pathogens were isolated in 51 percent of evaluable cases; Campylobacter (29 percent) and Salmonella (16 percent) were the most frequent pathogens. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examining all culture-positive patients, there was a modest reduction in time to cure with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      (1.7 versus 2.8 days). The benefit was somewhat more pronounced in patients classified as being severely ill (1.5 versus 3.4 days) but there was no difference in the mean time until clinical cure in the subset of patients with Salmonella infection (6.5 versus 6.4 days).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"       Norfloxacin",
"      </a>",
"      was less likely than placebo to result in elimination of Salmonella from the stool on day 12 to 17 (18 versus 49 percent), and the median time to negative cultures was prolonged in the norfloxacin group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study was unusual in that enteric pathogens were identified in 51 percent of evaluable cases compared with the usual rate of pathogen isolation (eg, 1.5 to 5.6 percent, (",
"    <a class=\"graphic graphic_table graphicRef82535 \" href=\"mobipreview.htm?31/25/32156\">",
"     table 1",
"    </a>",
"    )), due to the fact that the majority of the patients had traveler's diarrhea, as 70 percent had traveled abroad within the previous six weeks.",
"   </p>",
"   <p>",
"    The lack of benefit in otherwise healthy patients with nontyphoidal salmonella gastroenteritis noted in this trial was confirmed in a meta-analysis of 12 trials with 778 participants, including 258 infants and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Enterohemorrhagic E. coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with suspected or proven infection with enterohemorrhagic E. coli (EHEC). There is no evidence of benefit from antibiotic therapy for EHEC infection and there is concern about an increase in the risk of hemolytic-uremic syndrome that might be mediated by an increase in the production or release of Shiga toxin when antibiotics are administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/40\">",
"     40",
"    </a>",
"    ]. EHEC infection should be suspected in patients with bloody diarrhea, abdominal pain and tenderness, but little or no fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clostridium difficile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute diarrhea should be questioned carefully about prior antibiotic therapy and other risk factors for C. difficile infection. The appropriate therapy for this infection is discontinuation of antibiotics, if possible, and consideration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    if the symptoms are more than mild or worsen or persist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Listeria monocytogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria may present with diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic illness. If cultured, treatment should be administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . Although the latter may be more effective for treatment of listeriosis, it interferes with metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and therefore should be used with caution in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     When to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2001 IDSA practice guidelines concluded that any consideration of antimicrobial therapy must be carefully weighed against unintended and potentially harmful consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to treat with empiric antibiotic therapy in the following groups is based on randomized controlled trials showing benefit with a significant reduction in duration of diarrhea and other symptoms, practice guidelines, and overwhelming clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5,9,38,41-44\">",
"     5,9,38,41-44",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with moderate to severe travelers' diarrhea as characterized by more than four unformed stools daily, fever, blood, pus, or mucus in the stool. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"       \"Travelers' diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Those with more than eight stools per day, volume depletion, symptoms for more than one week, those in whom hospitalization is being considered, and immunocompromised hosts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric antibiotics can also be considered in patients who present with signs and symptoms of bacterial diarrhea such as fever, bloody diarrhea (except, as noted above, for suspected EHEC or C. difficile infection), and the presence of occult blood or fecal leukocytes in the stool.",
"   </p>",
"   <p>",
"    We recommend empiric therapy with an oral fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400 mg twice daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg once daily) for three to five days in the absence of suspected EHEC or fluoroquinolone-resistant campylobacter infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5,9,11,38,44\">",
"     5,9,11,38,44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (500 mg PO once daily for three days) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg PO twice daily for five days) are alternative agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/44\">",
"     44",
"    </a>",
"    ], particularly if fluoroquinolone resistance is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Specific antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of specific intestinal pathogens is discussed in detail on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimotility agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (Imodium) may be used for the symptomatic treatment of patients with acute diarrhea in whom fever is absent or low grade and the stools are not bloody. In two randomized controlled studies, loperamide compared with placebo significantly decreased the number of liquid bowel movements or diarrhea when given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The dose of loperamide is two tablets (4 mg) initially, then 2 mg after each unformed stool, not to exceed 16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for &le;2 days.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"     Diphenoxylate",
"    </a>",
"    (Lomotil) is an alternative agent, but it has not been studied in randomized controlled studies. The dose of diphenoxylate is two tablets (4 mg) four times daily for &le;2 days.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"     Diphenoxylate",
"    </a>",
"    has central opiate effects and may cause cholinergic side effects. In addition, patients should be cautioned that treatment with these agents may mask the amount of fluid lost, since fluid may pool in the intestine. Thus, fluids should be used aggressively when antimotility agents are employed.",
"   </p>",
"   <p>",
"    Another potential problem is that both drugs may facilitate the development of the hemolytic-uremic syndrome (HUS) in patients infected with EHEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     Bismuth",
"    </a>",
"    subsalicylate (Pepto-Bismol) has also been used for symptomatic treatment of acute diarrhea. When compared with placebo, bismuth subsalicylate significantly reduced the number of unformed stools and increased the proportion of patients free of symptoms at the end of treatment trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, in studies that compared bismuth subsalicylate with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    , loperamide brought significantly faster relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/49,52,53\">",
"     49,52,53",
"    </a>",
"    ]. A role for bismuth subsalicylate may be in patients with significant fever and dysentery, conditions in which loperamide should be avoided. The dose of bismuth subsalicylate is 30 mL or two tablets every 30 minutes for eight doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics, including bacteria that assist in recolonizing the intestine with non-pathogenic flora, can also be used as alternative therapy. Probiotics have been shown to be useful in treating traveler's diarrhea and acute non-specific diarrhea in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of specific dietary recommendations other than oral hydration discussed above has not been well-established in controlled trials. However, adequate nutrition during an episode of acute diarrhea is important to facilitate enterocyte renewal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/34\">",
"     34",
"    </a>",
"    ]; if patients are anorectic, a short period of consuming only liquids will not be harmful. Boiled starches and cereals (eg, potatoes, noodles, rice, wheat, and oat) with salt are indicated in patients with watery diarrhea; crackers, bananas, soup, and boiled vegetables may also be consumed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"     10",
"    </a>",
"    ]. Foods with high fat content should also be avoided until the gut function returns to normal after a severe bout of diarrhea.",
"   </p>",
"   <p>",
"    In addition, secondary lactose malabsorption is common following infectious enteritis and may last for several weeks to months. Thus, temporary avoidance of lactose-containing foods may be reasonable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .) The benefit of attempting to repopulate the bowel flora with yogurt containing live cultures or other probiotics is unproven in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=see_link\">",
"       \"Patient information: Diarrhea in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/63/31730?source=see_link\">",
"       \"Patient information: E. coli (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/29/36308?source=see_link\">",
"       \"Patient information: Acute diarrhea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation of patients with acute diarrhea should include looking for evidence of extracellular volume depletion (eg, decreased skin turgor, orthostatic hypotension), a careful history to determine the duration of symptoms, and presence of fever and peritoneal signs, which may be clues to infection with an invasive enteric pathogen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnostic evaluation is indicated in patients with relatively severe illness, bloody diarrhea, or high risk patients (eg, elderly or immunocompromised). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's history can be useful in identifying the pathogens associated with an episode of acute diarrhea and may help to guide empiric therapy when it is indicated. A food history including consumption of unpasteurized dairy products, raw or undercooked meat or fish, or organic vitamin preparations may suggest certain pathogens (",
"      <a class=\"graphic graphic_table graphicRef75543 graphicRef55625 \" href=\"mobipreview.htm?26/29/27101\">",
"       table 3A-B",
"      </a>",
"      ). In addition, the timing of symptoms with regard to exposure to suspected offending food can be important clues to the diagnosis (",
"      <a class=\"graphic graphic_table graphicRef56595 \" href=\"mobipreview.htm?31/24/32140\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Historical clues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have evaluated the accuracy of fecal leukocytes alone or in combination with occult blood testing. The ability of these tests to predict the presence of an inflammatory diarrhea has varied greatly. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fecal leukocytes and occult blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend obtaining stool cultures on initial presentation in immunocompromised patients (HIV-infected, elderly, patients with comorbidities or with underlying inflammatory bowel disease), those with severe or bloody diarrhea, and in food handlers. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'When to obtain stool cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sending stool samples for ova and parasites is",
"      <strong>",
"       not",
"      </strong>",
"      cost effective for the majority of patients with acute diarrhea. However, we recommend ova and parasite study in patients with persistent diarrhea, in men who have sex with men, during a community waterborne outbreak (associated with Giardia and Cryptosporidium), or with bloody diarrhea with few or no fecal leukocytes (associated with intestinal amebiasis). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'When to obtain stool for ova and parasites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with acute diarrhea begins with general measures such as hydration and alteration of diet. We recommend",
"      <strong>",
"       no",
"      </strong>",
"      antibiotic therapy in most cases. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend empiric antibiotic therapy for patients with moderate to severe travelers' diarrhea, those with signs and symptoms of invasive bacterial diarrhea such as fever and bloody diarrhea, the elderly, and immunocompromised hosts. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend",
"      <strong>",
"       no",
"      </strong>",
"      antibiotic treatment for patients with suspected or proven infection with enterohemorrhagic E. coli (EHEC). (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If empiric therapy is warranted, we recommend treatment with a fluoroquinolone for three to five days in the absence of suspected EHEC or campylobacter infection. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If campylobacter is suspected we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      as alternative agents, given high rates of fluoroquinolone resistance (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Directed antibiotic therapy should be administered when an intestinal pathogen is identified. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'When to treat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Specific antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the antimotility agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      (Imodium) be used for the symptomatic treatment of patients with acute diarrhea in whom fever is absent or low grade and the stools are not bloody. (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Symptomatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/1\">",
"      Bern C, Martines J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrhoeal disease: a ten-year update. Bull World Health Organ 1992; 70:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/2\">",
"      Yip R, Sharp TW. Acute malnutrition and high childhood mortality related to diarrhea. Lessons from the 1991 Kurdish refugee crisis. JAMA 1993; 270:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/3\">",
"      Cohen ML. The epidemiology of diarrheal disease in the United States. Infect Dis Clin North Am 1988; 2:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/4\">",
"      Ho MS, Glass RI, Pinsky PF, et al. Diarrheal deaths in American children. Are they preventable? JAMA 1988; 260:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/5\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/6\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/7\">",
"      Feldman RA, Banatvala N. The frequency of culturing stools from adults with diarrhoea in Great Britain. Epidemiol Infect 1994; 113:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/8\">",
"      Jones TF, Bulens SN, Gettner S, et al. Use of stool collection kits delivered to patients can improve confirmation of etiology in foodborne disease outbreaks. Clin Infect Dis 2004; 39:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/9\">",
"      Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996; 22:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/10\">",
"      DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/11\">",
"      Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004; 350:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/12\">",
"      Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/13\">",
"      Chitkara YK, McCasland KA, Kenefic L. Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital. Arch Intern Med 1996; 156:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/14\">",
"      Stoll BJ, Glass RI, Banu H, et al. Value of stool examination in patients with diarrhoea. Br Med J (Clin Res Ed) 1983; 286:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/15\">",
"      Siegel D, Cohen PT, Neighbor M, et al. Predictive value of stool examination in acute diarrhea. Arch Pathol Lab Med 1987; 111:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/16\">",
"      Huicho L, Sanchez D, Contreras M, et al. Occult blood and fecal leukocytes as screening tests in childhood infectious diarrhea: an old problem revisited. Pediatr Infect Dis J 1993; 12:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/17\">",
"      Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990; 150:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/18\">",
"      Herbert ME. Medical myth: Measuring white blood cells in the stools is useful in the management of acute diarrhea. West J Med 2000; 172:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/19\">",
"      Guerrant RL, Shields DS, Thorson SM, et al. Evaluation and diagnosis of acute infectious diarrhea. Am J Med 1985; 78:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/20\">",
"      Savola KL, Baron EJ, Tompkins LS, Passaro DJ. Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. J Clin Microbiol 2001; 39:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/21\">",
"      Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992; 30:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/22\">",
"      Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/23\">",
"      Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/24\">",
"      Koplan JP, Fineberg HV, Ferraro MJ, Rosenberg ML. Value of stool cultures. Lancet 1980; 2:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/25\">",
"      Rohner P, Pittet D, Pepey B, et al. Etiological agents of infectious diarrhea: implications for requests for microbial culture. J Clin Microbiol 1997; 35:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/26\">",
"      Barbut F, Beaugerie L, Delas N, et al. Comparative value of colonic biopsy and intraluminal fluid culture for diagnosis of bacterial acute colitis in immunocompetent patients. Infectious Colitis Study Group. Clin Infect Dis 1999; 29:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/27\">",
"      DeGirolami PC, Ezratty CR, Desai G, et al. Diagnosis of intestinal microsporidiosis by examination of stool and duodenal aspirate with Weber's modified trichrome and Uvitex 2B strains. J Clin Microbiol 1995; 33:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/28\">",
"      Hart AS, Ridinger MT, Soundarajan R, et al. Novel organism associated with chronic diarrhoea in AIDS. Lancet 1990; 335:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/29\">",
"      Siegel DL, Edelstein PH, Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA 1990; 263:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/30\">",
"      ASGE Standards of Practice Committee, Shen B, Khan K, et al. The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc 2010; 71:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/31\">",
"      Avery ME, Snyder JD. Oral therapy for acute diarrhea. The underused simple solution. N Engl J Med 1990; 323:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/32\">",
"      Carpenter CC, Greenough WB, Pierce NF. Oral-rehydration therapy--the role of polymeric substrates. N Engl J Med 1988; 319:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/33\">",
"      Santosham M, Burns B, Nadkarni V, et al. Oral rehydration therapy for acute diarrhea in ambulatory children in the United States: a double-blind comparison of four different solutions. Pediatrics 1985; 76:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/34\">",
"      Duggan C, Santosham M, Glass RI. The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. Centers for Disease Control and Prevention. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/35\">",
"      de Zoysa I, Kirkwood B, Feachem R, Lindsay-Smith E. Preparation of sugar-salt solutions. Trans R Soc Trop Med Hyg 1984; 78:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/36\">",
"      Santosham M, Keenan EM, Tulloch J, et al. Oral rehydration therapy for diarrhea: an example of reverse transfer of technology. Pediatrics 1997; 100:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/37\">",
"      Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000; 343:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/38\">",
"      Wistr&ouml;m J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 1992; 117:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/39\">",
"      Sirinavin S, Garner P. Antibiotics for treating salmonella gut infections. Cochrane Database Syst Rev 2000; :CD001167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/40\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"    <li>",
"     Wanke, C, Guerrant, R. Infectious gastroenteritis. In: Medicine for the Practicing Physician, 4th ed, Hurst, J (Ed), Appleton &amp; Lange, Stamford, CT 1996. p. 340.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/42\">",
"      Tong MJ, Martin DG, Cunningham JJ, Gunning JJ. Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA 1970; 214:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/43\">",
"      Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/44\">",
"      Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/45\">",
"      Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin-resistant campylobacter infection. J Infect Dis 2004; 190:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/46\">",
"      Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/47\">",
"      Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993; 118:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/48\">",
"      Cimolai N, Carter JE, Morrison BJ, Anderson JD. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990; 116:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/49\">",
"      Steffen R. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea. Rev Infect Dis 1990; 12 Suppl 1:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/50\">",
"      Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology 1983; 85:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/51\">",
"      DuPont HL, Sullivan P, Pickering LK, et al. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 1977; 73:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/52\">",
"      DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990; 88:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32025/abstract/53\">",
"      Johnson PC, Ericsson CD, DuPont HL, et al. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA 1986; 255:757.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2717 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32025=[""].join("\n");
var outline_f31_17_32025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications for diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Historical clues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fecal leukocytes and occult blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fecal lactoferrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      When to obtain stool cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Processing stool cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When to obtain stool for ova and parasites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral rehydration solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Enterohemorrhagic E. coli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clostridium difficile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Listeria monocytogenes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - When to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Specific antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2717\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2717|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/23/18800\" title=\"algorithm 1\">",
"      Workup of acute diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2717|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/25/32156\" title=\"table 1\">",
"      Stool culture isolates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/7/42107\" title=\"table 2\">",
"      Enteric pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/28/26060\" title=\"table 3A\">",
"      Intestinal pathogen exposure I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/44/14028\" title=\"table 3B\">",
"      Intestinal pathogen exposure II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/24/32140\" title=\"table 4\">",
"      Food poisoning GI sxs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23943?source=related_link\">",
"      Aeromonas infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6313?source=related_link\">",
"      Epidemiology of viral gastroenteritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22373?source=related_link\">",
"      Microbiology and pathogenesis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5065?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/63/31730?source=related_link\">",
"      Patient information: E. coli (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_17_32026="Overview of the management of chronic kidney disease in children";
var content_f31_17_32026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of chronic kidney disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Tarak Srivastava, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/17/32026/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/17/32026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) refers to a state of irreversible kidney damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of kidney function, which can be progressive. CKD is now the accepted term in the pediatric nephrology community, replacing the clinical terms of chronic renal failure (CRF) and chronic renal insufficiency (CRI), which describe kidney dysfunction of varying degrees from severe to mild in nature. CKD more clearly defines kidney dysfunction as a continuum, rather than a discrete change in kidney function and will be used throughout this topic review.",
"   </p>",
"   <p>",
"    An overview of the management of CKD in children will be reviewed here. The etiology, epidemiology, natural course, presentation and evaluation of CKD in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26919?source=see_link\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    has defined CKD as a disorder lasting three or more months with either kidney damage defined by structural or functional renal abnormalities, or an estimated glomerular filtration rate (GFR) of less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that many of the complications of CKD can be prevented or delayed through early detection and treatment prompted the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup to develop a formal staging system for stratification of CKD for patients greater than two years of age. This classification schema is based upon the level of kidney function as follows (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"mobipreview.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 disease &ndash; Normal GFR (&ge;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2;)",
"     </li>",
"     <li>",
"      Stage 2 disease &ndash; GFR between 60 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2;",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2;",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2;",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2; or end-stage renal disease (ESRD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal levels of GFR vary with age, gender, and body size. GFR increases with maturation from infancy and approaches adult mean values by two years of age (",
"    <a class=\"graphic graphic_table graphicRef55965 \" href=\"mobipreview.htm?19/61/20443\">",
"     table 2",
"    </a>",
"    ). Children under two years of age do not fit within the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification system because they normally have a low GFR even when corrected for body surface area. In these patients, calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect kidney impairment.",
"   </p>",
"   <p>",
"    The GFR can be estimated by using the Schwartz formula, which is based upon serum creatinine, age, height, and in adolescents, the gender of the patient (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?23/40/24193?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    GFR = k X Height (cm)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Screat",
"   </p>",
"   <p>",
"    Height represents the body height measured in centimeters, and Screat is the serum creatinine in",
"    <span class=\"nowrap\">",
"     mg/dl.",
"    </span>",
"    The constant k is directly proportional to the muscle component of body, and varies with age. The estimated GFR (eGFR) also depends on the laboratory assay used to measure serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/2\">",
"     2",
"    </a>",
"    ]. Minor fluctuations are common in eGFR but a change of &gt;25 percent from baseline should be considered significant, and an evaluation for reversible causes of renal dysfunction should be considered. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The value for k is 0.33 in premature infants through the first year of life, 0.45 for term infants through the first year of life, 0.55 in children and adolescent girls, and 0.7 in adolescent boys are used when serum creatinine is measured by Jaffe method.",
"     </li>",
"     <li>",
"      The value for k is 0.413 for all children with CKD between ages 1 and 16 years when the clinical laboratory reports serum creatinine measured by the enzymatic method and normalized to isotope-dilution mass spectrometry (IDMS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26919?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Definitions and classifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of the patient with chronic kidney disease (CKD) includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treat reversible kidney dysfunction",
"     </li>",
"     <li>",
"      Prevent or slow the progression of kidney disease",
"     </li>",
"     <li>",
"      Treat the complications of CKD",
"     </li>",
"     <li>",
"      Identify and adequately prepare the",
"      <span class=\"nowrap\">",
"       child/family",
"      </span>",
"      in whom renal replacement therapy will be required",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of implementing these components varies primarily upon the severity of CKD.",
"   </p>",
"   <p>",
"    In the early stages of CKD, there is an opportunity to treat any reversible cause of kidney dysfunction, and prevent or slow the progression of kidney disease. Children with stages 1 and 2 disease are asymptomatic and should be closely followed for deterioration of kidney function. This period should also be used to educate the child and family about CKD, highlighting awareness of risk factors that can aggravate kidney failure (eg, nephrotoxic drugs, recurrent infections, dehydration, obesity, and smoking in adolescents) and of measures that may slow the progression of kidney failure (eg, blood pressure and diabetes control).",
"   </p>",
"   <p>",
"    CKD-associated complications begin to appear as CKD progresses into stage 3. These include disorders of fluid and electrolytes, renal osteodystrophy, anemia, hypertension, dyslipidemia, endocrine abnormalities, growth impairment, and disorders due to the decreased clearance of substances normally excreted from the body by the kidney (uremia). In these patients, management is focused on preventing and treating these complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Complications of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who will require renal replacement therapy (RRT) should be identified well in advance of the time that RRT is required so that adequate preparation and education can be provided to both the patient and family. This generally occurs in patients with stage 4 CKD. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Renal replacement therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup has established clinical practice guidelines for a number of conditions associated with CKD, which were updated by the Kidney Disease: Improving Global Outcome (KDIGO) 2012 Clinical Practice Guidelines for the Evaluation and Management of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In general, this discussion on the management of children with CKD is based upon these guidelines that can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    and the KDIGO web site at",
"    <a class=\"external\" href=\"file://www.kdigo.org/clinical_practice_guidelines/CKD.php\">",
"     file://www.kdigo.org/clinical_practice_guidelines/CKD.php",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REVERSIBLE KIDNEY DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with chronic kidney disease (CKD), identification and treatment of reversible causes of acute or chronic kidney dysfunction may result in some recovery of kidney function, if addressed early in the course.",
"   </p>",
"   <p>",
"    The most common conditions with potentially recoverable kidney function are primarily due to decreased kidney perfusion or the administration of nephrotoxic agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased kidney perfusion &ndash; Kidney hypoperfusion is produced by hypotension (eg, septic shock), volume depletion from vomiting, diarrhea, diuretic use, or bleeding, and the administration of drugs that lower the kidney perfusion (such as nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme [ACE] inhibitors, angiotensin II receptor blockers [ARBs]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10985?source=see_link\">",
"       \"Chapter 2D: Regulation of GFR and renal plasma flow\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The normal response to kidney hypoperfusion is to lower the urine sodium concentration and the fractional excretion of sodium. However, the superimposition of a prerenal process among patients with CKD may not result in the expected lowering of urinary sodium because the renal tubular sodium reabsorption is impaired. As a result, patients with CKD who are unable to normally reabsorb sodium are less able to respond to conditions associated with fluid loss or hypotension leading to an increased risk of reduced kidney perfusion and glomerular filtration rate (GFR). These patients should be identified at the onset of an intercurrent illness associated with hypovolemia or hypotension so that fluid repletion can be initiated prior to a significant decrease in kidney blood flow. If significant hypovolemia accompanied by a reduction of GFR occurs, a judicious trial of fluid repletion may result in the return of kidney function to the previous baseline. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of nephrotoxic drugs &ndash; Common nephrotoxic drugs include nonsteroidal anti-inflammatory agents, diagnostic agents (eg, radiographic contrast materials), and others (eg, aminoglycosides,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ). The administration of such drugs, therefore, should be avoided or used with caution in patients with underlying CKD, with the assistance of therapeutic drug level monitoring. When drugs that have a narrow therapeutic index are used and precision in dosing is critical (eg, cisplatinum in bone marrow transplant induction protocol) based on renal function, measurement of GFR should be made using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"       iohexol",
"      </a>",
"      or one of the radioisotopes (",
"      <sup>",
"       51",
"      </sup>",
"      Cr-EDTA,",
"      <sup>",
"       125",
"      </sup>",
"      Iothalamate or",
"      <sup>",
"       99",
"      </sup>",
"      Tc-DTPA). In this situation, drug dosing ideally should not be based on an estimated GFR using a regression equation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=see_link\">",
"       \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H5#H5\">",
"       \"Assessment of kidney function\", section on 'Measurement of GFR'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Certain drugs, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/8/5255?source=see_link\">",
"       trimethoprim",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"       flucytosine",
"      </a>",
"      , lead to an elevation in serum creatinine but not blood urea nitrogen (BUN), as they interfere with either the tubular secretion of creatinine or the laboratory assay for creatinine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SLOWING CHRONIC KIDNEY DISEASE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic kidney disease (CKD), progressive long-term kidney damage is in part due to adaptive hyperfiltration with increased intraglomerular perfusion and pressure. The kidney injury is manifested histologically by glomerular scarring (glomerulosclerosis). The progression of CKD is greatest during the two periods of rapid growth: infancy and puberty. These events place increased demands upon the preexistent compromised kidney function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26919?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Natural history and progression of chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults and children with CKD, strict blood pressure control has been shown to slow the progression of kidney disease and reduce the risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In particular, ACE inhibitors and ARBs have been suggested as antihypertensive therapy to reduce proteinuria and control blood pressure in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that hypertension be strictly controlled with antihypertensive therapy in children with CKD based upon the beneficial effect that blood pressure control has in reducing the progression of CKD in both children and adults. We suggest that patients with hypertension and proteinuria be treated with an ACE inhibitor or an ARB as there is evidence in adult studies and limited evidence in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/6-10\">",
"     6-10",
"    </a>",
"    ] that these agents appear to be more protective than other antihypertensive drugs in this clinical setting. The management of hypertension is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional interventions that have been studied in adults with CKD include dietary protein restriction, lipid lowering therapy, and correction of anemia. However, results are inconclusive with respect to the impact of these interventions upon delaying the progression of CKD. In children, data have not shown a benefit of a low protein diet upon the progression of kidney disease. In a two year prospective, stratified, and randomized multicenter study of 191 children with CKD, the institution of a low-protein diet (0.8 to 1.1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    failed to have an impact on the decline in creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/11\">",
"     11",
"    </a>",
"    ]. The current consensus by pediatric nephrology experts is to provide children with CKD the age appropriate recommended daily allowance for protein. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Nutrition'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of complications result as a consequence of the loss of kidney function. These include disorders of fluid and electrolyte balance, renal osteodystrophy, hypertension, anemia, dyslipidemia, growth impairment, malnutrition and risk of poor neurodevelopmental outcome",
"   </p>",
"   <p>",
"    The management of these abnormalities in children will be discussed in this section. The pathophysiology, evaluation and monitoring of these abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Complications of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Evaluation at presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Follow-up evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sodium and intravascular volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;As glomerular filtration rate (GFR) becomes severely decreased (ie, stages 4 and 5 disease), water and sodium retention may result in volume overload. In general, a combination of dietary sodium restriction and diuretic therapy may correct the increased water balance and prevent water retention from recurring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Sodium and water balance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current recommendation for adequate daily sodium intake in healthy children is only 1.2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for four to eight year-old children and 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/12\">",
"     12",
"    </a>",
"    ]. This amount is substantially lower than the average current intake of a normal, healthy child in the United States.",
"   </p>",
"   <p>",
"    In our practice, we work with the child and family to decrease the sodium intake to 2 to 3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This is often a difficult task given the sodium content of the current favorite foods of children. Diuretic therapy includes either loop diuretics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    given at a dose of 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or thiazide diuretics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    at 1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. At our center, we typically use a thiazide diuretic in the early stages of CKD and a loop diuretic in the more advanced stages of disease when the thiazides are less effective. Both classes of diuretics become less effective with decreasing GFR.",
"   </p>",
"   <p>",
"    Some children with obstructive uropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysplastic kidneys have poor urinary concentrating capacity and exhibit urinary sodium wasting, resulting in a propensity for hypovolemia and hyponatremia. These children may continue to have substantial urine output despite water losses and require ongoing fluid and sodium replacement. Small children and infants who are unable to independently access or indicate the need for fluids are totally dependent upon caretakers for fluid replacement. The need for fluid replacement should be emphasized to the caretakers, especially when the child has an intercurrent illness that increases volume losses (eg, diarrhea) or decreases fluid intake (eg, vomiting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia develops primarily because of inadequate potassium excretion due to a reduced GFR. Other factors that can contribute to elevated potassium levels include a high dietary potassium intake, increased tissue breakdown, metabolic acidosis, hypoaldosteronism (due in some cases to administration of an ACE inhibitor or an ARB), or an impaired cellular uptake of potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management to prevent hyperkalemia in children with CKD consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low potassium diet.",
"     </li>",
"     <li>",
"      Administration of a loop diuretic (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      ) to increase urinary potassium loss.",
"     </li>",
"     <li>",
"      If there is metabolic acidosis, oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to correct acidosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Metabolic acidosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In infants under selected circumstances, formula can be mixed with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/38/5733?source=see_link\">",
"       sodium polystyrene sulfonate",
"      </a>",
"      and decanted externally to decrease the potassium content of the formula prior to feeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/13\">",
"       13",
"      </a>",
"      ]. The use of sodium polystyrene sulfonate in this manner is a common practice in many pediatric nephrology centers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal replacement therapy must be considered if conservative management fails to control hyperkalemia.",
"   </p>",
"   <p>",
"    The medical treatment of acute hyperkalemia in children is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4279?source=see_link\">",
"     \"Management of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia is uncommon in children with CKD. However, it can be observed in children in the early stages of CKD associated with Fanconi syndrome, renal tubular acidosis, or from excessive diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=see_link\">",
"     \"Overview of renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, overt acidosis is characteristically present when the estimated GFR is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2; (ie, stage 4 disease). Acidosis is associated with growth impairment because the body utilizes bone buffering to bind some of the excess hydrogen ions.",
"   </p>",
"   <p>",
"    Current guidelines by the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO working groups are to maintain the serum bicarbonate level at or above 22",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. We suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy in patients with metabolic acidosis to achieve this targeted goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"     14",
"    </a>",
"    ]. Sodium bicarbonate therapy is started at 1 to 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    per day in two to three divided doses, and the dose is titrated to the clinical target. Citrate preparations should, on the other hand, be used with caution in children with CKD, as these preparations enhance aluminum absorption from the intestine and increase the risk of aluminum toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bone metabolism and bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in mineral metabolism and bone structure are an almost universal finding with progressive CKD due to abnormalities in the metabolism of calcium, phosphate, vitamin D, parathyroid hormone (PTH), and fibroblast growth factor-23 (FGF-23) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. If these abnormalities are not addressed, these changes result in kidney bone disease, referred to as renal osteodystrophy. Significant morbidity may be associated with renal osteodystrophy, including growth failure, avascular necrosis, and skeletal fractures and deformities.",
"   </p>",
"   <p>",
"    The prevention and management of bone disease in children with CKD are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressures (BP) in children by developing blood pressure percentiles based on gender, age, and height (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"     table 4",
"    </a>",
"    ). Hypertension (HTN) is defined as either systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic BP &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile measured upon three or more occasions",
"   </p>",
"   <p>",
"    The prevalence of hypertension in children with CKD is high, even when the GFR is only mildly reduced, and increases with further declines in GFR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, data from the Chronic Kidney Disease in Children (CKiD) study showed a prevalence rate of HTN of 37 percent in children between 1 and 16 years of age with a GFR between 30 to 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m&sup2; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/16\">",
"       16",
"      </a>",
"      ]. Only a third of the patients received anti-hypertensive therapy. In another report from the CKiD study, 38 percent of children with CKD had masked hypertension (normal office BP but elevated ambulatory BP) and 18 percent had confirmed hypertension (both elevated office and ambulatory BP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/17\">",
"       17",
"      </a>",
"      ]. These data suggest that although we are aware of the importance of BP in CKD, underdiagnosing and inadequate control of BP persist in children with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HTN was observed in two-thirds of a cross-sectional sample of patients (age range 1 to 21 years) six months after initiation of chronic dialysis who were enrolled in the North American Pediatric Renal Trials and Collaborative Studies registry from 1992 to 2008 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/18\">",
"       18",
"      </a>",
"      ]. Hypertension was observed despite the use of antihypertensive agents in 58 percent of the cohort. Multivariate analysis found that factors associated with both uncontrolled systolic and diastolic HTN (defined as &gt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, height and gender) included use of antihypertensive medication at six months after initiation of dialysis, glomerular disease as the primary cause of CKD, black ethnicity, and younger age (&lt;6 years). There was a trend of improved BP control over the study period of 16 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, aggressive blood pressure control slows the progression of CKD. This was illustrated in the ESCAPE trial of 385 children with CKD (GFR between 15 and 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2;) that randomly assigned patients to intensified (target: 24-hour mean arterial pressure [MAP] below the 50",
"    <sup>",
"     th",
"    </sup>",
"    percentile) or conventional blood pressure control (target: MAP between the 50",
"    <sup>",
"     th",
"    </sup>",
"    and 90",
"    <sup>",
"     th",
"    </sup>",
"    percentiles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/6\">",
"     6",
"    </a>",
"    ]. All patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (an angiotensin converting enzyme [ACE] inhibitor) at a dose of 6",
"    <span class=\"nowrap\">",
"     mg/m&sup2;",
"    </span>",
"    per day. Other antihypertensive agents that did not target the renin-angiotensin system were added to achieve targeted MAP goals, if needed.",
"   </p>",
"   <p>",
"    The following findings were noted at five-year follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children in the intensified BP control group were less likely to reach the primary endpoint of a decline of 50 percent in the GFR or ESRD compared to those in the conventional BP control group (30 versus 41 percent, hazard ratio 0.65, 95% CI 0.44-0.94).",
"     </li>",
"     <li>",
"      An initial 50 percent reduction in proteinuria after initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      therapy was highly predictive of a delay in the progression of CKD (hazard ratio 0.46, 95% CI 0.27-0.79).",
"     </li>",
"     <li>",
"      Factors that were associated with an increased likelihood of progressive CKD included a low baseline GFR, greater degree of proteinuria, higher 24-hour MAP, and age. After adjustment for these covariates, intensified BP control was still associated with a lower risk of CKD progression. The sub-groups that benefited the most from intensified versus conventional BP control were children with a diagnosis of glomerulopathies, baseline GFR &lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m&sup2; and annualized reduction of GFR &gt;3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year, and a urine protein to creatinine ratio &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/mg.",
"      </span>",
"     </li>",
"     <li>",
"      The mean number of antihypertensive agents per patient in addition to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      was greater in the intensified versus conventional treatment groups (0.9 versus 0.5).",
"     </li>",
"     <li>",
"      The target 24-hour MAP &lt;50",
"      <sup>",
"       th",
"      </sup>",
"      percentile was reached by 60, 73, 71, 72, and 74 percent of the intensive group by 12, 24, 36, 48 and 60 months. However, more than 50 percent of the conventional group also had a 24-hour MAP below the 50",
"      <sup>",
"       th",
"      </sup>",
"      percentile with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      monotherapy during the course of the study.",
"     </li>",
"     <li>",
"      Overall, the median urinary protein excretion was reduced during the first six months of the study, but gradually increased over time and was similar at three years to baseline values.",
"     </li>",
"     <li>",
"      There was no difference in adverse events between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, these findings were based upon mean 24-hour BP measurements, which are not routinely performed in all patients. Nevertheless, based upon these results, we recommend strict blood pressure control in all children with CKD. Treatment of hypertension should include specification of target blood pressure levels, nonpharmacologic therapy, and antihypertensive therapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Slowing chronic kidney disease progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Target blood pressure goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD, the NHBPEP has recommended a reduction in blood pressure to below the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile based upon the age, gender, and height of the patient (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines also recommend target systolic and diastolic blood pressures of less than 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, gender, and height, or less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg, whichever is lower. The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously discussed, the ESCAPE trial modified therapy based upon targeted 24-hour mean BP measurements that are not available in all patients. In patients with ambulatory BP monitoring (ABPM), we recommend targeting BPs to 24-hour mean BP &lt;50",
"    <sup>",
"     th",
"    </sup>",
"    percentile because of the significant benefit that was noted on CKD progression in the ESCAPE trial using this BP goal. However, it remains unclear how to extrapolate this goal to patients without 24-hour ABPM.",
"   </p>",
"   <p>",
"    Based upon the findings in the ESCAPE trial, the KDIGO guideline has, suggested a target BP goal for systolic and diastolic BP of less than or equal to the 50",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, sex and height, especially in children with proteinuria, unless limited by signs and symptoms of hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no published recommendations for adolescents with CKD whose BP is between",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg and",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg, and below the &lt;90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, height, and gender. In the absence of a clear guideline, we suggest that the blood pressure in adolescents with CKD be targeted to",
"    <span class=\"nowrap\">",
"     &le;120/80",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    In younger children, we continue to use the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines to target systolic and diastolic blood pressures of less than 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, gender, and height based on office blood pressure measurements. If 24-hour ABPM monitoring is available, we agree with the ESCAPE goal of a mean BP below the 50",
"    <sup>",
"     th",
"    </sup>",
"    percentile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ambulatory blood pressure monitoring (ABPM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;We frequently perform ambulatory blood pressure monitoring (ABPM) in children with CKD in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If consistent blood pressure data are difficult to obtain with office measurements",
"     </li>",
"     <li>",
"      To evaluate the efficacy of antihypertensive therapy, especially when hypertension is difficult to control",
"     </li>",
"     <li>",
"      If the patient is symptomatic with complaints that could be attributed to adverse effects from anti-hypertensive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=see_link\">",
"     \"Ambulatory blood pressure monitoring in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy includes both nonpharmacologic and pharmacologic interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic therapy &ndash; Treatment should be initiated with conservative measures such as weight reduction, exercise, and dietary salt reduction. KDIGO guidelines recommend that children with CKD who have hypertension or are pre-hypertensive should be restricted to the age-based recommended dietary sodium intake, which is 1.2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for four to eight year olds and 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for older children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4,19\">",
"       4,19",
"      </a>",
"      ]. This amount is substantially lower than the average current intake of a child. We work with the child and family to decrease the sodium intake to 2 to 3",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      which is often difficult given the sodium content of current favorite foods of children.",
"     </li>",
"     <li>",
"      Pharmacologic therapy &ndash; ACE inhibitors or angiotensin II receptor blockers (ARBs) may be used for treatment of hypertension in the earlier stages of CKD. They are the preferred antihypertensive agents as they appear to be more beneficial in slowing the progression of CKD compared to other agents in patients with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4,6,20-22\">",
"       4,6,20-22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Slowing chronic kidney disease progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we prefer to initiate therapy with an ACE inhibitor as there are more data on the safety and efficacy of this class of drugs compared to ARBs in children. We often start with an initial dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/18/32040?source=see_link\">",
"     enalapril",
"    </a>",
"    of 0.08",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum of 5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which is titrated to a maximum dose of 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum of 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    based upon the response of the patient's blood pressure and results of lab tests (eg, serum potassium). We use enalapril because its long half-life allows once a day dosing. Alternative, long-acting ACE inhibitors commonly used in children are",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/38/15976?source=see_link\">",
"     lisinopril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    , which are also administered once a day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data in children regarding ARB usage are limited. We use ARBs to replace ACE inhibitor in patients who have difficulty tolerating an ACE inhibitor (mostly adolescents) to treat hypertension and decrease proteinuria. We avoid combination therapy of ACE inhibitors and ARBs as data from adults suggest an increased likelihood of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both ACE inhibitors and ARBs should be used cautiously if the GFR is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/22\">",
"     22",
"    </a>",
"    ]. Since the decline in GFR induced by an ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    typically occurs within the first few days after the onset of therapy, the serum creatinine and potassium concentrations should be remeasured three to five days after the institution of therapy to ensure that the therapy has not adversely affected the GFR resulting in elevation of serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperkalemia.",
"   </p>",
"   <p>",
"    The teratogenic potential of these drugs in women of childbearing age also should be discussed with any postpubertal adolescent female when administration of either an ACE inhibitor or ARB is being considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diuretic is also often recommended in the early stages of CKD. The thiazide diuretics, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to a maximum of 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    become less effective as monotherapy as the GFR declines. Thus, a loop diuretic is recommended for the treatment of hypertension and edema in patients with more severe CKD. In our practice, we use the loop diuretic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    at a dose of 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in one to two divided doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia due to reduced kidney erythropoietin production generally develops when the GFR is below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2;. Data from the CKiD study suggests that hemoglobin begins to decline significantly when the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    -determined GFR is at 43",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2;, a value which equates with a Schwartz estimated GFR of 58",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m&sup2; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/23\">",
"     23",
"    </a>",
"    ]. At the onset of dialysis, the presence of anemia in children is very common and has been associated with excessive morbidity and an increased mortality risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because anemia is a common complication of children with severe CKD (ie, stages 4 and 5), the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO working groups established guidelines for the identification, evaluation, and treatment of anemia in children at all stages of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. The recommendations for the management of anemia presented here are based upon these sets of guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Screening and evaluation of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual testing hemoglobin (HGB) should be performed in children with CKD, regardless of stage or cause.",
"   </p>",
"   <p>",
"    A diagnosis of anemia is made when the observed HGB result is below the 5",
"    <sup>",
"     th",
"    </sup>",
"    percentile of normal adjusted for age and sex (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"     table 5",
"    </a>",
"    ). Once anemia is detected in a child with CKD, the following evaluation, which is focused upon eliminating causes of anemia other than CKD and determining the iron status of the patient, is recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red blood cell indices",
"     </li>",
"     <li>",
"      Reticulocyte count",
"     </li>",
"     <li>",
"      Iron parameters (serum iron, total iron binding capacity, percent transferrin saturation [TSAT] and serum ferritin)",
"     </li>",
"     <li>",
"      Test for occult blood in stool",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 KDIGO guideline suggested the following age-based HGB thresholds be used to define anemia in children with CKD age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0.5 to 5 years &ndash; &lt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      5 to 12 years &ndash; &lt;11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      12 to 15 years &ndash; &lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      &gt;15 years - &lt;13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (males) and &lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (females)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of anemia in children with CKD often includes iron supplementation and an erythropoiesis stimulating agent (ESA).",
"   </p>",
"   <p>",
"    Iron therapy (elemental iron 3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) should be initiated if iron deficiency is detected. Iron supplementation is targeted to maintain a TSAT &ge;20 percent and serum ferritin &ge;100",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    in children with CKD. All patients receiving therapy with an ESA, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/51/17208?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (rHuEPO) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21175?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    , require iron supplementation to prevent the development of iron deficiency. Once iron status is normal, it should be monitored at least every three months or monthly following the initiation of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increase in ESA dosing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although primarily used in patients with end-stage renal disease (ESRD), ESAs such as rHuEPO and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21175?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    are also used to correct the anemia in some children at earlier CKD stages. Increasing the HGB into an acceptable range in pediatric patients with anemia may ameliorate anemia-induced symptoms (eg, fatigue and exercise intolerance), result in cardiovascular improvement, and possibly decrease mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has recently recommended a HGB target range of 10 to 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    based upon the results of clinical trials conducted in adults with CKD. The optimal HGB for children with CKD who receive ESA therapy is unclear. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO guidelines recommend a target hemoglobin between 11 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    based upon consensus expert opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data suggest that children with CKD and a HGB less than 9.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    are at increased risk for mortality, left ventricular hypertrophy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased exercise capacity compared to those with a HGB greater than 9.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, quality of life and neurocognitive function has improved in patients treated with rHuEPO who experienced a significant increase in HGB compared to a baseline HGB which was below 9",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Data in adults have shown that HGB levels of 13",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    or higher are associated with an increased risk of significant adverse outcomes, particularly cardiovascular (CV) related events. As a result, there is a general consensus among expert panels throughout the world that adult targeted HGB levels should not exceed 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in patients treated with an ESA. The 2012 KDIGO anemia working group has suggested that ESAs not be used to maintain HGB levels &gt;11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in adult CKD patients and that their use is primarily intended to prevent the need for blood transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/28\">",
"     28",
"    </a>",
"    ]. In children, there are currently no data demonstrating an increased risk of CV deaths or events with HGB levels greater than 13",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    However, given the evidence of increased risk of CV death in children and adults with advanced stages of CKD, we agree with the recommended target of HGB between 11 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in children with CKD who receive therapy with an ESA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial rHuEPO dose in older children not receiving dialysis is 80 to 120",
"    <span class=\"nowrap\">",
"     u/kg",
"    </span>",
"    per week, administered in two to three divided doses. Children younger than five years of age or children receiving dialysis frequently require higher doses (as much as 300",
"    <span class=\"nowrap\">",
"     u/kg",
"    </span>",
"    per week). In predialysis patients and in those who receive peritoneal dialysis, rHuEPO should preferably be administered by the subcutaneous route and the site of injection should be rotated. In patients who receive hemodialysis, rHuEPO is typically administered intravenously through their vascular access.",
"   </p>",
"   <p>",
"    The response to rHuEPO is monitored by measurement of the HGB every one to two weeks following the initiation of treatment or following a dose change until a stable target HGB and a stable rHuEPO dose have been achieved; it should then be monitored every four weeks. The expected increase in HGB after the initiation of rHuEPO therapy or after a dose change is between 1.0 to 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    over a two to four week period.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21175?source=see_link\">",
"     Darbepoetin alfa",
"    </a>",
"    is a long-acting erythropoietic agent. Its threefold longer half-life and greater biological activity compared to epoetin-alfa or epoetin-beta allows for less frequent dosing to effectively maintain a target HGB. Based upon limited pediatric data, darbepoetin alfa can be given at a dose of 0.25 to 0.75",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    no more frequently than once weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. At present, our preference is to use darbepoetin alfa in adolescents as a means of improving compliance with medication administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common cause of an incomplete response to an ESA is iron deficiency. However, other conditions in the iron replete patient may cause an inadequate response to an ESA as well and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection or inflammation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic blood loss (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=see_link\">",
"       \"Approach to the child with anemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteitis fibrosa (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"       \"Pathogenesis of renal osteodystrophy\"",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      secondary hyperparathyroidism",
"     </li>",
"     <li>",
"      Aluminum toxicity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Folate or vitamin B12 deficiency (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Hemoglobinopathies",
"     </li>",
"     <li>",
"      Hemolysis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"       \"Overview of hemolytic anemias in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency (rare)",
"     </li>",
"     <li>",
"      Copper deficiency (rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal lipid metabolism is common in patients with CKD and adds to the risk for cardiovascular disease (CVD) (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). As a result, the American Academy of Pediatrics, American Heart Association, and an expert panel sponsored by the United States National Heart, Lung, and Blood Institute recommend that all children greater than two years of age with one or more known atherosclerotic risks or conditions associated with CVD (including CKD) be screened for dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link&amp;anchor=H5#H5\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all children, measures to prevent dyslipidemia include diet (",
"    <a class=\"graphic graphic_table graphicRef78256 \" href=\"mobipreview.htm?3/49/3870\">",
"     table 6",
"    </a>",
"    ) and daily exercise. A more restrictive diet is suggested for children with CKD stage 5 disease (",
"    <a class=\"graphic graphic_table graphicRef82404 \" href=\"mobipreview.htm?30/43/31419\">",
"     table 7",
"    </a>",
"    ). In children &ge;10 years of age with persistent dyslipidemia (ie, persistently elevated low density lipoprotein [LDL] cholesterol) despite nonpharmacologic therapy, statin therapy may be indicated. Screening for pediatric dyslipidemia and its management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=see_link\">",
"     \"Definition and screening for dyslipidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is common in children with CKD because of poor appetite, decreased intestinal absorption of nutrients, and metabolic acidosis. Attention to nutrition is critical as it affects both the physical growth and neurocognitive development of children.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    pediatric guidelines for nutrition recommend that the nutritional status of children with CKD should be evaluated on a periodic basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"     14",
"    </a>",
"    ]. The frequency of monitoring is primarily dependent upon the age of the patient and CKD stage as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0 to 1 year of age:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CKD stages 2-5: From 0.5 to 3 months",
"     </li>",
"     <li>",
"      CKD stage 5D (eg, dialysis patients): From 0.5 to 2 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1 to 3 years of age for all stages including dialysis patients: From 1 to 3 months",
"     </li>",
"     <li>",
"      &gt;3 years of age:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CKD stage 2: From 6 to 12 months",
"     </li>",
"     <li>",
"      CKD stage 3: Every 6 months",
"     </li>",
"     <li>",
"      CKD stage 4, 5 and 5D: From 3 to 4 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following parameters are measured:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary intake (three-day diet record or three 24-hour dietary recalls)",
"     </li>",
"     <li>",
"      Estimated dry weight and weight for age percentile or standard deviation score (SDS)",
"     </li>",
"     <li>",
"      Length or height for age percentile or SDS",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Weight/height",
"      </span>",
"      index",
"     </li>",
"     <li>",
"      Body mass index (BMI) for height age percentile or SDS",
"     </li>",
"     <li>",
"      In patients younger than three years of age, head circumference for age percentile or SDS",
"     </li>",
"     <li>",
"      Normalized protein catabolic rate in hemodialyzed adolescents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nutritional therapy based upon growth parameters should be developed for each child with CKD and ideally be coordinated by a dietician with expertise in pediatrics and renal nutrition. Nutritional management should address the energy, protein, vitamin, mineral and electrolyte needs of the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial prescribed energy (calorie) intake for children with CKD is based upon the estimated energy requirement (EER) for chronological age (",
"    <a class=\"graphic graphic_table graphicRef56276 \" href=\"mobipreview.htm?27/59/28603\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"     14",
"    </a>",
"    ]. Further supplementation should be considered when the initial intake fails to meet the child's energy requirements and",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is not achieving expected rates of weight gain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth. Although supplementation by the oral route is preferred, one may have to resort to tube feedings with a nasogastric tube, transpyloric tube, or gastrostomy to ensure adequate energy intake (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    ). A trial of intradialytic parental nutrition may be considered in children undergoing chronic hemodialysis therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein intake should be between 100 to 140 percent of the Dietary Reference Intake (DRI) based upon age and gender for children with CKD stage 3 and between 100 and 120 percent for those with CKD stages 4 and 5 (",
"    <a class=\"graphic graphic_table graphicRef81506 \" href=\"mobipreview.htm?21/52/22348\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"     14",
"    </a>",
"    ]. For patients on peritoneal dialysis, protein intake should be higher (additional 0.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) to compensate for dialytic protein loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/31/28153?source=see_link&amp;anchor=H797529#H797529\">",
"     \"Chronic peritoneal dialysis in children\", section on 'Nutritional and metabolic issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protein restriction is not recommended in children as it has not been shown to influence the decrease in kidney function in children with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/31\">",
"     31",
"    </a>",
"    ]. Supplementation should be considered if the oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enteral protein intake is inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/11,14,32\">",
"     11,14,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a two year prospective, stratified, and randomized multicenter study of 191 children with CKD, the institution of a low-protein diet (0.8 to 1.1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    failed to have an impact on the decline in creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, in a small clinical trial of 24 infants with CKD, patients receiving a low-protein diet (1.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) showed a significantly lower height SDS and height velocity SDS compared to those patients receiving a higher protein intake (2.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Vitamins and minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CKD should receive 100 percent of the DRIs for the vitamins: thiamine (B1), riboflavin (B2), pyridoxine (B6), vitamin B12, A, C, E, K, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"mobipreview.htm?11/20/11585\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"mobipreview.htm?19/31/19967\">",
"     table 11",
"    </a>",
"    ); and the minerals: copper and zinc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"     14",
"    </a>",
"    ]. In children with advanced CKD (ie, stage 5), the loss of renal clearance of vitamin A metabolites places these children at risk for developing hypervitaminosis A; these children should receive a water-soluble vitamin supplement with the addition of vitamin A only in patients with very low dietary intake .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure has been long recognized in children with CKD. While the institution of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rHuGH) therapy can have a profound effect on the height velocity of children with CKD who are growing poorly, early recognition and management of malnutrition, renal osteodystrophy, acid-base abnormalities and electrolyte disturbances should take place prior to considering the institution of rHuGH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17240?source=see_link\">",
"     \"Prevention and management of growth failure in children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36713?source=see_link\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neurodevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremia is associated with alterations in cognition and may impact neurodevelopment in children. Neurologic findings can range from seizures and severe intellectual disability (mental retardation) to subtle deficits resulting in poor school performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/34\">",
"     34",
"    </a>",
"    ]. The cognitive disturbance in an older child may present with abnormal performance on tasks of verbal abstract ability, visual perceptual reasoning, memory, and visual motor skills. In the Chronic Kidney Disease in Children (CKiD) cohort study, of 368 children with mild to moderate CKD, neurocognitive functioning was within the average range overall for the cohort; however, 21 percent to 40 percent of patients scored lower on one of the measures for intelligence quotient, academic achievement, attention regulation or executive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Neurodevelopment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurodevelopmental impairment can be minimized by optimizing nutritional, dialysis, and anemia management. Close follow-up must be maintained with attention to minute details. In infants and young children, frequent monitoring of head circumference and age-appropriate developmental evaluations are necessary. A more formal neurodevelopmental assessment is needed in older children, especially if they have poor school performance.",
"   </p>",
"   <p>",
"    In patients with neurodevelopmental impairment or learning disabilities, assessment of the general CKD management should be performed to identify other factors, such as anemia, that can negatively impact learning capacity. Educational support can be obtained by referral to early intervention programs for infants and young children or special education school services for older children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Uremic bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased tendency for bleeding is present in patients with severe CKD due primarily to abnormalities in platelet adhesion and aggregation properties. In asymptomatic patients, no specific therapy is required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in patients who are actively bleeding or who are about to undergo a surgical or invasive procedure (such as renal biopsy), the platelet abnormality should be addressed. A number of different treatment options can be considered in this setting. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/45/15062?source=see_link\">",
"       Desmopressin",
"      </a>",
"      (dDAVP), an analog of antidiuretic hormone that is the simplest and least toxic acute treatment. It is administered intravenously or subcutaneously at a dose of 0.3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      with an onset of effect within one hour of administration; the effect lasts for six to eight hours.",
"     </li>",
"     <li>",
"      Cryoprecipitate (1 to 2",
"      <span class=\"nowrap\">",
"       units/10",
"      </span>",
"      kg); the effect lasts for 24 to 36 hours, but there is an increased risk of transmitted infectious diseases.",
"     </li>",
"     <li>",
"      Estrogen (0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 5 days); the onset of effect is over 6 to 24 hours, but the effect lasts for two to three weeks.",
"     </li>",
"     <li>",
"      Correction of anemia; as an improved hemoglobin (hematocrit) is believed to facilitate increased interaction between platelets and blood vessels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Uremic pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic pericardial disease (pericarditis and pericardial effusion) is seen only in the late stages of CKD and is an indication to institute dialysis. Most patients with uremic pericarditis respond rapidly to dialysis with resolution of chest pain as well as a decrease in the size of the pericardial effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=see_link\">",
"     \"Pericarditis in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342439969\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;All childhood vaccinations should be administered in children with CKD with the caveat that live attenuated vaccines should NOT be administered to children on immunosuppressive therapy. As an example,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14502?source=see_link\">",
"     live attenuated influenza vaccine",
"    </a>",
"    should not be given to children undergoing dialysis or with CKD, but instead, the inactivated version should be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4\">",
"     4",
"    </a>",
"    ]. The pneumococcal vaccine should be given to all children with nephrotic syndrome and those with CKD. In addition, hepatitis B vaccination should be provided to all children with CKD or undergoing dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the estimated glomerular filtration rate (GFR) declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2; (stage 4 CKD), it is time to start preparing the child and the family for renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/1\">",
"     1",
"    </a>",
"    ]. The family should be provided with information related to preemptive kidney transplantation, peritoneal dialysis, and hemodialysis.",
"   </p>",
"   <p>",
"    As in adults, some form of renal replacement therapy will generally be needed when the GFR falls below 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2; (stage 5 CKD). However, renal replacement therapy is often initiated before children reach these levels for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor total calorie intake resulting in failure to thrive",
"     </li>",
"     <li>",
"      Clinical symptoms attributable to uremia",
"     </li>",
"     <li>",
"      Delay in psychomotor development",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      development of educational issues from progressive CKD",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Choice of renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of replacement therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12774?source=see_link\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD), as is true for any chronic condition, impacts the quality of life for both the child and family. A survey of 402 families of 2 to 16 year-old children with mild to moderate CKD (median glomerular filtration rate [GFR] 42.5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2;) of median duration of seven years found an overall low health related quality of life in children with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/36\">",
"     36",
"    </a>",
"    ]. They scored lower compared to their healthy peers in all of the four domains tested: physical, school, emotional, and social.",
"   </p>",
"   <p>",
"    In particular, psychological and social stresses are found in children with CKD and their families. The normal progression of the child to independence is impeded, and concerns about body composition and image are greatly magnified in children whose growth and pubertal development are delayed or altered, especially those who undergo chronic dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/37\">",
"     37",
"    </a>",
"    ]. The prospect of a lifetime with renal replacement therapy (dialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transplant) and the potential for catastrophic complications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death makes it difficult to achieve normal childhood and adolescent developmental goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This difficulty continues into adulthood as demonstrated in a study of 144 adults who had childhood ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/40\">",
"     40",
"    </a>",
"    ]. Compared to age-matched population normative data, these patients were twice as likely to be unemployed (19 versus 11 percent), and those who were employed were at a lower occupational level.",
"   </p>",
"   <p>",
"    The negative impact of chronic disease on the emotional status of the patient's siblings is also well recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/41\">",
"     41",
"    </a>",
"    ]. These siblings frequently feel \"neglected\" because the parents must provide substantial physical and psychological support to the sick child. Furthermore, the well child may simultaneously feel jealous of the attention provided to the sick child, as well as guilt about being well while the sibling is severely ill.",
"   </p>",
"   <p>",
"    Optimal comprehensive management of these issues involves a multidisciplinary approach that proactively addresses these concerns. Key members of the team include social workers and mental health specialists.",
"   </p>",
"   <p>",
"    When, on a rare occasion, parents of a child with Stage 5 CKD elect conservative management and death over a lifetime of dialysis and transplantation for their child, this should be considered a choice that may, on occasion, be medically, ethically, and legally acceptable. A host of factors need to be considered by the family, the healthcare providers, and often the institution's ethics committee. When a decision to forego renal replacement therapy is deemed acceptable, the family should be supported emotionally and provided with whatever care is necessary to maintain the child in a pain-free state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/17/32026/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=see_link\">",
"     \"Palliative care: End-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/17/24850?source=see_link\">",
"       \"Patient information: Bone problems caused by kidney disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=see_link\">",
"       \"Patient information: Medicines for chronic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of children with chronic kidney disease (CKD) includes treating any reversible kidney dysfunction, preventing or slowing the progression of CKD, treating the complications associated with CKD, and identifying and preparing patients and their families for whom renal replacement therapy will be required. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, comprehensive management includes addressing the psychological and social stresses on the family and child in dealing with a chronic condition. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Quality of life'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Reversing kidney dysfunction and slowing CKD progression",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most conditions with potentially recoverable kidney function are primarily due to decreased kidney perfusion or the administration of nephrotoxic agents, which may be corrected with either volume repletion or discontinuation of a nephrotoxic drug. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Reversible kidney dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults and children with CKD, strict blood pressure control has been shown to slow the progression of kidney disease and decrease the risk of cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with CKD, there is no evidence that a low protein diet slows the progression of kidney disease. There is also concern that such a diet may impair growth. We suggest that children with CKD be given a daily diet containing 100 percent of the dietary reference intake for protein based upon age and gender (",
"      <a class=\"graphic graphic_table graphicRef81506 \" href=\"mobipreview.htm?21/52/22348\">",
"       table 9",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Slowing chronic kidney disease progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume overload &ndash; In children with severe CKD and volume overload due to water retention, we suggest a combination trial of dietary sodium restriction and diuretic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our practice, we limit the sodium intake to 2 to 3",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      Thiazide diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/29/42454?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ) are preferred in the early stages of CKD, while",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      or another loop diuretic is used in more advanced stages of CKD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sodium and intravascular volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemia &ndash; In children with moderate to severe CKD, we recommend a low potassium diet to prevent hyperkalemia (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Other interventions include the use of loop diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      ) and correction of metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic acidosis &ndash; In children with CKD and metabolic acidosis, we suggest administering",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to maintain a serum bicarbonate level &ge;22",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal osteodystrophy &ndash; Renal osteodystrophy can be managed with ongoing monitoring of bone metabolism (measurements of serum concentrations of calcium, phosphorus, and parathyroid hormone levels) and appropriate therapeutic interventions including vitamin D replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28042?source=see_link\">",
"       \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that high blood pressure (BP) in children with CKD be avoided, and BP be strictly controlled (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In patients with hypertension and proteinuria, we suggest that an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) be used rather than other classes of antihypertensive agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our practice, we use target systolic and diastolic blood pressures of less than 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, gender, and height based on office blood pressure measurements. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Slowing chronic kidney disease progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypertension'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Anemia &ndash; In children with CKD, testing of the hemoglobin (HGB) should be performed at least yearly. Anemia is defined as a HGB below the 5",
"      <sup>",
"       th",
"      </sup>",
"      percentile of normal adjusted for age and sex (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"       table 5",
"      </a>",
"      ). After eliminating other causes of anemia, treatment of anemia due to CKD includes iron supplementation and in patients with severe CKD, erythropoietin therapy.",
"      <br/>",
"      <br/>",
"      In children with CKD who receive therapy with an ESA, we suggest a target HGB between 11 and 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyslipidemia &ndash; Interventions should follow the recommendations of the American Heart Association and the American Academy of Pediatrics. We recommend an initial trial of nonpharmacologic therapy that includes diet (",
"      <a class=\"graphic graphic_table graphicRef82404 \" href=\"mobipreview.htm?30/43/31419\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"mobipreview.htm?3/49/3870\">",
"       table 6",
"      </a>",
"      ) and daily exercise (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest statin therapy be considered in patients greater than 10 years old with a persistently elevated low density lipoprotein (LDL) cholesterol level (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dyslipidemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12282?source=see_link\">",
"       \"Management of pediatric dyslipidemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Growth and nutrition &ndash; In children with CKD, ongoing monitoring of their nutritional status includes measurement of growth parameters and dietary review. We suggest that the diet contain 100 percent of the estimated energy intake based upon age and gender (",
"      <a class=\"graphic graphic_table graphicRef56276 \" href=\"mobipreview.htm?27/59/28603\">",
"       table 8",
"      </a>",
"      ), and appropriate protein requirement based upon age and CKD stage (",
"      <a class=\"graphic graphic_table graphicRef81506 \" href=\"mobipreview.htm?21/52/22348\">",
"       table 9",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In some patients with growth impairment,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/61/3032?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      is an option to improve linear growth. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Growth'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27881?source=see_link\">",
"       \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with CKD are at risk for neurodevelopmental impairment, which can be minimized by optimal nutritional and anemic management. Ongoing neurodevelopmental assessment is necessary to determined whether additional educational support is needed. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Neurodevelopment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Renal replacement options",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the patient reaches CKD stage 4 disease (glomerular filtration rate &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m&sup2;), it is time to start preparing the child and the family for renal replacement therapy. At this time, information related to preemptive kidney transplantation, peritoneal dialysis, and hemodialysis is provided to the family. The choice among renal replacement options is dictated by technical, social, and compliance issues, and family preference. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Renal replacement therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/2\">",
"      Srivastava T, Alon US, Althahabi R, Garg U. Impact of standardization of creatinine methodology on the assessment of glomerular filtration rate in children. Pediatr Res 2009; 65:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/3\">",
"      Schwartz GJ, Mu&ntilde;oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/4\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/5\">",
"      Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999; 246:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/6\">",
"      ESCAPE Trial Group, W&uuml;hl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/7\">",
"      W&uuml;hl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 2008; 23:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/8\">",
"      Franscini LM, Von Vigier RO, Pfister R, et al. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens 2002; 15:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/9\">",
"      Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 1988; 112:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/10\">",
"      Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/11\">",
"      Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117.",
"     </a>",
"    </li>",
"    <li>",
"     Panel of Dietary Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. National Academic Press, Washington, DC 2004. Available at: www.nap.edu/books/0309091691/ (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/13\">",
"      Bunchman TE, Wood EG, Schenck MH, et al. Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake. Pediatr Nephrol 1991; 5:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/14\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure: 2008 Update. Am J Kidney Dis 2009; 53(Suppl 2):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/15\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46(Suppl1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/16\">",
"      Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/17\">",
"      Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/18\">",
"      Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr 2012; 160:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/19\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/20\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/21\">",
"      White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 2003; 18:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/22\">",
"      Soergel M, Verho M, W&uuml;hl E, et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol 2000; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/23\">",
"      Fadrowski JJ, Pierce CB, Cole SR, et al. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008; 3:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/24\">",
"      Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 2003; 18:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/25\">",
"      K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/26\">",
"      NKF-K/DOQI Clinical Practice Guidelines and Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/27\">",
"      McMurray J, Parfrey PS and et al. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/28\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guidline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/29\">",
"      De Palo T, Giordano M, Palumbo F, et al. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/30\">",
"      Warady BA, Arar MY, Lerner G, et al. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol 2006; 21:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/31\">",
"      Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev 2007; :CD006863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/32\">",
"      Kist-van Holthe tot Echten JE, Nauta J, Hop WC, et al. Protein restriction in chronic renal failure. Arch Dis Child 1993; 68:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/33\">",
"      Uauy RD, Hogg RJ, Brewer ED, et al. Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 1994; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/34\">",
"      Lawry KW, Brouhard BH, Cunningham RJ. Cognitive functioning and school performance in children with renal failure. Pediatr Nephrol 1994; 8:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/35\">",
"      Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/36\">",
"      Gerson AC, Wentz A, Abraham AG, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 2010; 125:e349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/37\">",
"      Tjaden L, Tong A, Henning P, et al. Children's experiences of dialysis: a systematic review of qualitative studies. Arch Dis Child 2012; 97:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/38\">",
"      Brownbridge G, Fielding DM. Psychosocial adjustment and adherence to dialysis treatment regimes. Pediatr Nephrol 1994; 8:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/39\">",
"      Reynolds JM, Garralda ME, Jameson RA, Postlethwaite RJ. How parents and families cope with chronic renal failure. Arch Dis Child 1988; 63:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/40\">",
"      Groothoff JW, Grootenhuis MA, Offringa M, et al. Social consequences in adult life of end-stage renal disease in childhood. J Pediatr 2005; 146:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/41\">",
"      Stewart DA, Stein A, Forrest GC, Clark DM. Psychosocial adjustment in siblings of children with chronic life-threatening illness: a research note. J Child Psychol Psychiatry 1992; 33:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/17/32026/abstract/42\">",
"      Cohen C. Ethical and legal considerations in the care of the infant with end-stage renal disease whose parents elect conservative therapy. An American perspective. Pediatr Nephrol 1987; 1:166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6085 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32026=[""].join("\n");
var outline_f31_17_32026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REVERSIBLE KIDNEY DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SLOWING CHRONIC KIDNEY DISEASE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHRONIC KIDNEY DISEASE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sodium and intravascular volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bone metabolism and bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Target blood pressure goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ambulatory blood pressure monitoring (ABPM)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Screening and evaluation of anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Energy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neurodevelopment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Uremic bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Uremic pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H342439969\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Choice of renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Reversing kidney dysfunction and slowing CKD progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Renal replacement options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6085|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/61/20443\" title=\"table 2\">",
"      Normal GFR children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7894\" title=\"table 3\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7910\" title=\"table 4\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/34/5679\" title=\"table 5\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/49/3870\" title=\"table 6\">",
"      Pediatric diet to prevent CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/43/31419\" title=\"table 7\">",
"      Diet CKD dyslipidemia child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/59/28603\" title=\"table 8\">",
"      Energy intake CKD children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/52/22348\" title=\"table 9\">",
"      Protein intake CKD children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/20/11585\" title=\"table 10\">",
"      Water sol vit DRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/31/19967\" title=\"table 11\">",
"      Fat sol vit DRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?23/40/24193?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by Schwartz formula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 3\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=related_link\">",
"      Ambulatory blood pressure monitoring in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/31/28153?source=related_link\">",
"      Chronic peritoneal dialysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4279?source=related_link\">",
"      Management of hyperkalemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=related_link\">",
"      Palliative care: End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36713?source=related_link\">",
"      Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/17/24850?source=related_link\">",
"      Patient information: Bone problems caused by kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=related_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17240?source=related_link\">",
"      Prevention and management of growth failure in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_17_32027="Aspirin 10 yr risk levels";
var content_f31_17_32027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    10-year CHD risk levels at which the number of cardiovascular disease events prevented is closely balanced to the number of serious bleeding events",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-year CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-year stroke risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-59 y",
"       </td>",
"       <td>",
"        &ge;4",
"       </td>",
"       <td>",
"        55-59 y",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-69 y",
"       </td>",
"       <td>",
"        &ge;9",
"       </td>",
"       <td>",
"        60-69 y",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70-79 y",
"       </td>",
"       <td>",
"        &ge;12",
"       </td>",
"       <td>",
"        70-79 y",
"       </td>",
"       <td>",
"        &ge;11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Shared decision making is strongly encouraged with persons whose risk is close to (either above or below) these estimates of 10-year risk levels. As the potential cardiovascular disease reduction benefit increases above harms, the recommendation to take aspirin should become stronger.",
"    <div class=\"footnotes\">",
"     CHD: coronary heart disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement. AHRQ Publication No. 09-05129-EF-2, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32027=[""].join("\n");
var outline_f31_17_32027=null;
var title_f31_17_32028="Pretransplant lab evaluation SOT";
var content_f31_17_32028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The pretransplant laboratory evaluation for solid organ transplant candidates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tests to obtain in all transplant candidates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Serologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella-zoster virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B virus: HBsAg, HBsAb, HBcAb*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis C virus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treponema pallidum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma gondii (in heart transplant candidates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinalysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculin skin test or interferon-gamma release assay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sputum stains and cultures for bacteria, mycobacteria, and fungi (in lung transplant candidates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tests to obtain from transplant candidates with exposures in endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Serologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strongyloides stercoralis (generally use empiric therapy for all patients with risk factors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leishmania spp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histoplasma capsulatum (in lung transplant candidates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coccidioides immitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trypanosoma cruzi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stool ova and parasites for Strongyloides stercoralis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine ova and parasites (and cystoscopy) for Schistosoma spp (for kidney transplants)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; HBcAb: hepatitis B core antibody.",
"     <br>",
"      * For individuals with known infection or at increased risk for infection (based on risk factors detected in the medical and/or social history), quantitative nucleic acid testing should also be performed.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32028=[""].join("\n");
var outline_f31_17_32028=null;
var title_f31_17_32029="Heart failure predicts sudden cardiac death and mortality";
var content_f31_17_32029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart failure predicts increased sudden cardiac death and overall mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a 38-year old follow-up of subjects in the Framingham Heart Study, the presence of heart failure (HF) significantly increased sudden death and overall mortality in both men and women.",
"    <div class=\"footnotes\">",
"     * p &lt;0.01.",
"     <br>",
"      &bull; p &lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kannel WB, Wilson PWF, D'Agostino RB, et al. Am Heart J 1998; 136:205.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32029=[""].join("\n");
var outline_f31_17_32029=null;
var title_f31_17_32030="PEG rHuMGDF in myelosuppression";
var content_f31_17_32030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Benefit of PEG-rHuMGDF in myelosuppressed mice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of PEG-rHuMGDF (red lines) or placebo (blue lines) on the platelet, white blood cell (WBC), and red blood cell (RBC) counts in mice treated with a combination of carboplatin and sublethal irradiation. Mice treated with PEG-rHuMGDF had accelerated recovery of all blood cell lineages and reduced mortality (15 versus 94 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hokom, MM, Lacey, D, Kinstler, OB, et al, Blood 1995; 86:4486.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32030=[""].join("\n");
var outline_f31_17_32030=null;
var title_f31_17_32031="Traumatic hemotympanum";
var content_f31_17_32031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemotympanum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the very dark fluid filling the middle ear space behind the tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_17_32031=[""].join("\n");
var outline_f31_17_32031=null;
